



US009393419B2

(12) **United States Patent**
Libbus et al.

(10) **Patent No.:** **US 9,393,419 B2**
(45) **Date of Patent:** **Jul. 19, 2016**

(54) **IMPLANTABLE
NEUROSTIMULATOR-IMPLEMENTED
METHOD FOR ENHANCING HEART
FAILURE PATIENT AWAKENING THROUGH
VAGUS NERVE STIMULATION**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,330,507 A 7/1994 Schwartz
5,522,854 A 6/1996 Idecker et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO2010005482 A1 1/2010

OTHER PUBLICATIONS

PCT Application No. PCT/US2015/020116, Search Report and Written Opinion dated Jul. 6, 2015, 12 pages.

(Continued)

Primary Examiner — George Evanisko

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(71) Applicant: **CYBERONICS, INC.**, Houston, TX (US)

(72) Inventors: **Imad Libbus**, St. Paul, MN (US); **Badri Amurthur**, Los Gatos, CA (US); **Bruce H. KenKnight**, Maple Grove, MN (US)

(73) Assignee: **CYBERONICS, INC.**, Houston, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/547,342**

(22) Filed: **Nov. 19, 2014**

(65) **Prior Publication Data**

US 2015/0073511 A1 Mar. 12, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/673,811, filed on Nov. 9, 2012, now Pat. No. 8,923,964.

(51) **Int. Cl.**

A61N 1/36 (2006.01)

A61B 5/00 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61N 1/36139** (2013.01); **A61B 5/0205** (2013.01); **A61B 5/4836** (2013.01); **A61B 5/686** (2013.01); **A61N 1/36053** (2013.01);

(Continued)

(58) **Field of Classification Search**


CPC A61N 1/36114; A61N 1/36117

See application file for complete search history.

(57) **ABSTRACT**

An implantable neurostimulator-implemented method for managing tachyarrhythmias upon a patient's awakening from sleep through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers comprising the cervical vagus nerve of a patient. Operating modes of the pulse generator are stored. An enhanced dose of the electrical therapeutic stimulation is parametrically defined and tuned to prevent initiation of or disrupt tachyarrhythmia upon the patient's awakening from a sleep state through at least one of continuously-cycling, intermittent and periodic ON-OFF cycles of electrical pulses. Other operating modes, including a maintenance dose and a restorative dose are defined. The patient's physiological state is monitored via at least one sensor to detect the patient's awakening, which activates the delivery of the enhanced dose.

20 Claims, 5 Drawing Sheets



| | | | | | | | | | |
|------|-------------------------|---|---------|----------------------|----|---------|-------------------|--|--|
| (51) | Int. Cl. | | | | | | | | |
| | <i>A61B 5/0205</i> | (2006.01) | | 7,395,119 | B2 | 7/2008 | Hagen et al. | | |
| | <i>A61B 5/11</i> | (2006.01) | | 7,403,819 | B1 | 7/2008 | Shelchuk et al. | | |
| | <i>A61N 1/362</i> | (2006.01) | | 7,418,292 | B2 | 8/2008 | Shafer | | |
| | <i>A61B 5/0452</i> | (2006.01) | | 7,452,800 | B2 | 11/2008 | Sosnowchik et al. | | |
| | <i>A61B 5/0464</i> | (2006.01) | | 7,480,532 | B2 | 1/2009 | Kieval et al. | | |
| | <i>A61B 5/08</i> | (2006.01) | | 7,481,759 | B2 | 1/2009 | Whitehurst et al. | | |
| | | | | 7,485,104 | B2 | 2/2009 | Kieval | | |
| | | | | 7,493,167 | B2 | 2/2009 | Hussein et al. | | |
| (52) | U.S. Cl. | | | 7,499,742 | B2 | 3/2009 | Bolea et al. | | |
| | CPC | <i>A61N1/36057</i> (2013.01); <i>A61N 1/36114</i> | | 7,499,747 | B2 | 3/2009 | Kieval et al. | | |
| | | (2013.01); <i>A61N 1/36157</i> (2013.01); <i>A61B</i> | | 7,499,748 | B2 | 3/2009 | Moffitt et al. | | |
| | | <i>5/0452</i> (2013.01); <i>A61B 5/0464</i> (2013.01); | | 7,502,650 | B2 | 3/2009 | Kieval | | |
| | | <i>A61B 5/08</i> (2013.01); <i>A61B 5/0816</i> (2013.01); | | 7,542,800 | B2 | 6/2009 | Libbus et al. | | |
| | | <i>A61B 5/1118</i> (2013.01); <i>A61B 5/4809</i> | | 7,548,780 | B2 | 6/2009 | Libbus et al. | | |
| | | (2013.01); <i>A61N 1/3621</i> (2013.01) | | 7,551,958 | B2 | 6/2009 | Libbus et al. | | |
| | | | | 7,561,922 | B2 | 7/2009 | Cohen et al. | | |
| | | | | 7,561,923 | B2 | 7/2009 | Libbus et al. | | |
| | | | | 7,570,999 | B2 | 8/2009 | Libbus et al. | | |
| (56) | References Cited | | | 7,582,053 | B2 | 9/2009 | Gross et al. | | |
| | U.S. PATENT DOCUMENTS | | | 7,584,004 | B2 | 9/2009 | Caparso et al. | | |
| | | | | 7,587,238 | B2 | 9/2009 | Moffitt et al. | | |
| | | | | 7,606,622 | B2 | 10/2009 | Reeve | | |
| | | | | 7,613,511 | B2 | 11/2009 | Wu et al. | | |
| | 5,707,400 | A | 1/1998 | Terry, Jr. et al. | | | | | |
| | 5,928,272 | A | 7/1999 | Adkins et al. | | | | | |
| | 5,978,709 | A | 11/1999 | Begemann et al. | | | | | |
| | 6,006,134 | A | 12/1999 | Hill et al. | | | | | |
| | 6,266,564 | B1 | 7/2001 | Hill et al. | | | | | |
| | 6,354,991 | B1 | 3/2002 | Gross et al. | | | | | |
| | 6,449,507 | B1 | 9/2002 | Hill et al. | | | | | |
| | 6,473,644 | B1 | 10/2002 | Terry, Jr. et al. | | | | | |
| | 6,508,771 | B1 | 1/2003 | Padmanabhan et al. | | | | | |
| | 6,522,926 | B1 | 2/2003 | Kieval et al. | | | | | |
| | 6,600,954 | B2 | 7/2003 | Cohen et al. | | | | | |
| | 6,610,713 | B2 | 8/2003 | Tracey | | | | | |
| | 6,616,624 | B1 | 9/2003 | Kieval | | | | | |
| | 6,622,041 | B2 | 9/2003 | Terry, Jr. et al. | | | | | |
| | 6,652,449 | B1 | 11/2003 | Gross et al. | | | | | |
| | 6,684,105 | B2 | 1/2004 | Cohen et al. | | | | | |
| | 6,690,971 | B2 | 2/2004 | Schauerte et al. | | | | | |
| | 6,712,772 | B2 | 3/2004 | Cohen et al. | | | | | |
| | 6,718,208 | B2 | 4/2004 | Hill et al. | | | | | |
| | 6,838,471 | B2 | 1/2005 | Tracey | | | | | |
| | 6,839,594 | B2 | 1/2005 | Cohen et al. | | | | | |
| | 6,850,801 | B2 | 2/2005 | Kieval et al. | | | | | |
| | 6,862,480 | B2 | 3/2005 | Cohen et al. | | | | | |
| | 6,892,098 | B2 | 5/2005 | Ayal et al. | | | | | |
| | 6,896,651 | B2 | 5/2005 | Gross et al. | | | | | |
| | 6,904,318 | B2 | 6/2005 | Hill et al. | | | | | |
| | 6,907,295 | B2 | 6/2005 | Gross et al. | | | | | |
| | 6,963,773 | B2 | 11/2005 | Borschowa et al. | | | | | |
| | 6,963,779 | B1 | 11/2005 | Shankar | | | | | |
| | 6,985,774 | B2 | 1/2006 | Kieval et al. | | | | | |
| | 7,010,345 | B2 | 3/2006 | Hill et al. | | | | | |
| | 7,072,720 | B2 | 7/2006 | Puskas | | | | | |
| | 7,123,961 | B1 | 10/2006 | Kroll et al. | | | | | |
| | 7,136,705 | B1 | 11/2006 | Park | | | | | |
| | 7,139,607 | B1 | 11/2006 | Shelchuk | | | | | |
| | 7,158,832 | B2 | 1/2007 | Kieval et al. | | | | | |
| | 7,184,828 | B2 | 2/2007 | Hill et al. | | | | | |
| | 7,184,829 | B2 | 2/2007 | Hill et al. | | | | | |
| | 7,189,204 | B2* | 3/2007 | Ni A61B 5/0205 | | | | | |
| | | | | 600/300 | | | | | |
| | 7,218,964 | B2 | 5/2007 | Hill et al. | | | | | |
| | 7,221,979 | B2 | 5/2007 | Zhou et al. | | | | | |
| | 7,225,017 | B1 | 5/2007 | Shelchuk | | | | | |
| | 7,225,019 | B2 | 5/2007 | Jahns et al. | | | | | |
| | 7,237,320 | B2 | 7/2007 | Lam | | | | | |
| | 7,245,967 | B1 | 7/2007 | Shelchuk | | | | | |
| | 7,260,431 | B2 | 8/2007 | Libbus et al. | | | | | |
| | 7,269,457 | B2 | 9/2007 | Shafer et al. | | | | | |
| | 7,277,761 | B2 | 10/2007 | Shelchuk | | | | | |
| | 7,295,881 | B2 | 11/2007 | Cohen et al. | | | | | |
| | 7,305,265 | B2 | 12/2007 | Fukui | | | | | |
| | 7,321,793 | B2 | 1/2008 | Ben Ezra et al. | | | | | |
| | 7,324,853 | B2 | 1/2008 | Ayal et al. | | | | | |
| | 7,336,997 | B2 | 2/2008 | Fukui | | | | | |
| | 7,346,398 | B2 | 3/2008 | Gross et al. | | | | | |
| | 7,387,603 | B2 | 6/2008 | Gross et al. | | | | | |
| | 7,389,149 | B2 | 6/2008 | Rossing et al. | | | | | |
| | | | | 7,650,190 | B2 | 1/2010 | Zhou et al. | | |
| | | | | 7,657,312 | B2 | 2/2010 | Pastore | | |
| | | | | 7,660,628 | B2 | 2/2010 | Libbus et al. | | |
| | | | | 7,664,548 | B2 | 2/2010 | Amurthur et al. | | |
| | | | | 7,668,602 | B2 | 2/2010 | Ben-David et al. | | |
| | | | | 7,672,733 | B2 | 3/2010 | Zhou et al. | | |
| | | | | 7,676,275 | B1 | 3/2010 | Farazi et al. | | |
| | | | | 7,684,866 | B2 | 3/2010 | Fowler et al. | | |
| | | | | 7,689,286 | B2 | 3/2010 | Pastore et al. | | |
| | | | | 7,711,415 | B1 | 5/2010 | Farazi et al. | | |
| | | | | 7,711,421 | B2 | 5/2010 | Shafer et al. | | |
| | | | | 7,734,355 | B2 | 6/2010 | Cohen et al. | | |
| | | | | 7,751,884 | B2 | 7/2010 | Ternes et al. | | |
| | | | | 7,769,442 | B2 | 8/2010 | Shafer | | |
| | | | | 7,769,446 | B2 | 8/2010 | Moffitt et al. | | |
| | | | | 7,778,702 | B2 | 8/2010 | Ben-David et al. | | |
| | | | | 7,778,703 | B2 | 8/2010 | Gross et al. | | |
| | | | | 7,778,711 | B2 | 8/2010 | Ben-David et al. | | |
| | | | | 7,783,353 | B2 | 8/2010 | Libbus et al. | | |
| | | | | 7,797,041 | B2 | 9/2010 | Libbus et al. | | |
| | | | | 7,801,603 | B2 | 9/2010 | Westlund et al. | | |
| | | | | 7,801,604 | B2 | 9/2010 | Brockway et al. | | |
| | | | | 7,801,614 | B2 | 9/2010 | Rossing et al. | | |
| | | | | 7,805,193 | B2 | 9/2010 | Libbus et al. | | |
| | | | | 7,805,203 | B2 | 9/2010 | Ben-David | | |
| | | | | 7,813,805 | B1 | 10/2010 | Farazi | | |
| | | | | 7,813,812 | B2 | 10/2010 | Kieval et al. | | |
| | | | | 7,835,797 | B2 | 11/2010 | Rossing et al. | | |
| | | | | 7,840,266 | B2 | 11/2010 | Libbus et al. | | |
| | | | | 7,840,271 | B2 | 11/2010 | Kieval et al. | | |
| | | | | 7,844,346 | B2 | 11/2010 | Cohen et al. | | |
| | | | | 7,848,812 | B2 | 12/2010 | Crowley et al. | | |
| | | | | 7,848,816 | B1 | 12/2010 | Wenzel et al. | | |
| | | | | 7,869,869 | B1 | 1/2011 | Farazi | | |
| | | | | 7,885,709 | B2 | 2/2011 | Ben-David | | |
| | | | | 7,885,711 | B2 | 2/2011 | Ben-Ezra et al. | | |
| | | | | 7,890,185 | B2 | 2/2011 | Cohen et al. | | |
| | | | | 7,894,907 | B2 | 2/2011 | Cowan et al. | | |
| | | | | 7,904,151 | B2 | 3/2011 | Ben-David | | |
| | | | | 7,904,175 | B2 | 3/2011 | Scott et al. | | |
| | | | | 7,904,176 | B2 | 3/2011 | Ben-Ezra et al. | | |
| | | | | 7,908,008 | B2 | 3/2011 | Ben-David et al. | | |
| | | | | 7,916,013 | B2 | 3/2011 | Stevenson | | |

(56)

References Cited

U.S. PATENT DOCUMENTS

7,925,342 B2 4/2011 Amurthur et al.
7,925,352 B2 4/2011 Stack et al.
7,974,693 B2 7/2011 Ben-David et al.
8,005,542 B2 8/2011 Ben-Ezra et al.
8,005,545 B2 8/2011 Ben-David et al.
8,036,745 B2 10/2011 Ben-David et al.
8,060,197 B2 11/2011 Ben-David et al.
8,065,021 B2 11/2011 Gross et al.
8,083,663 B2 12/2011 Gross et al.
8,116,881 B2 2/2012 Cohen et al.
8,131,362 B2 3/2012 Moffitt et al.
8,160,701 B2 4/2012 Zhao et al.
8,160,705 B2 4/2012 Stevenson et al.
8,195,290 B2 6/2012 Brockway
8,224,436 B2 7/2012 Libbus et al.
8,249,711 B2 8/2012 Libbus et al.
8,369,943 B2 2/2013 Shuros et al.
8,386,038 B2 2/2013 Bianchi et al.
8,401,640 B2 3/2013 Zhao et al.
8,417,354 B2 4/2013 Zhang et al.
8,571,654 B2 10/2013 Libbus et al.
8,577,458 B1 11/2013 Libbus et al.
8,600,505 B2 12/2013 Libbus et al.
8,634,921 B2 1/2014 Chavan et al.
8,688,212 B2 4/2014 Libbus et al.
8,918,190 B2 12/2014 Libbus et al.
2002/0107553 A1 8/2002 Hill et al.
2003/0040774 A1* 2/2003 Terry, Jr. A61N 1/36114
607/2
2003/0153954 A1* 8/2003 Park A61N 1/365
607/17
2003/0171781 A1 9/2003 Florio et al.
2004/0199210 A1 10/2004 Shelchuk
2004/0210261 A1 10/2004 King et al.
2004/0215265 A1* 10/2004 Keizer A61B 5/024
607/17
2005/0049655 A1 3/2005 Boveja et al.
2005/0065553 A1 3/2005 Ben-Ezra et al.
2005/0125044 A1 6/2005 Tracey
2005/0131467 A1 6/2005 Boveja
2005/0165465 A1 7/2005 Pianca et al.
2005/0267542 A1 12/2005 David et al.
2006/0015153 A1 1/2006 Gliner et al.
2006/0100668 A1 5/2006 Ben-David et al.
2006/0190053 A1 8/2006 Dobak, III
2006/0206155 A1 9/2006 Ben-David et al.
2006/0253161 A1 11/2006 Libbus et al.
2007/0067004 A1 3/2007 Boveja et al.
2007/0093870 A1 4/2007 Maschino et al.
2007/0213773 A1 9/2007 Hill et al.
2007/0233194 A1 10/2007 Craig
2007/0255320 A1 11/2007 Inman et al.
2007/0276453 A1 11/2007 Hill et al.
2008/0015659 A1* 1/2008 Zhang A61N 1/3627
607/62
2008/0021503 A1 1/2008 Whitehurst et al.
2008/0033511 A1 2/2008 Dobak
2008/0051839 A1* 2/2008 Libbus A61B 5/02028
607/2
2008/0058874 A1 3/2008 Westlund et al.
2008/0061240 A1* 3/2008 Heuft G01F 23/00
250/343
2008/0132983 A1 6/2008 Cohen et al.
2008/0147140 A1* 6/2008 Ternes A61N 1/36071
607/48
2008/0183258 A1 7/2008 Inman
2008/0243196 A1 10/2008 Libbus et al.
2008/0319513 A1 12/2008 Pu et al.
2009/0030493 A1 1/2009 Colburn et al.
2009/0118777 A1 5/2009 Iki et al.
2009/0124848 A1 5/2009 Miazga
2009/0149900 A1 6/2009 Moffitt et al.
2009/0248097 A1 10/2009 Tracey et al.
2009/0270953 A1 10/2009 Ecker et al.
2009/0275956 A1 11/2009 Burnes et al.

2010/0010556 A1* 1/2010 Zhao A61N 1/36114
607/17
2010/0010603 A1 1/2010 Ben-David et al.
2010/0016919 A1 1/2010 Hill et al.
2010/0042173 A1 2/2010 Farazi et al.
2010/0114197 A1 5/2010 Burnes et al.
2010/0114203 A1 5/2010 Burnes et al.
2010/0114227 A1 5/2010 Cholette
2010/0174341 A1 7/2010 Bolea et al.
2010/0286740 A1 11/2010 Libbus et al.
2010/0331908 A1 12/2010 Farazi
2011/0015692 A1 1/2011 Libbus et al.
2011/0082514 A1 4/2011 Libbus et al.
2011/0098796 A1 4/2011 Ben-David et al.
2011/0224749 A1 9/2011 Ben-David et al.
2011/0257708 A1 10/2011 Kramer et al.
2011/0313488 A1 12/2011 Hincapie Ordonez et al.
2012/0143286 A1 6/2012 Hahn et al.
2012/0172742 A1 7/2012 Arcot-Krishnamurthy et al.
2012/0185007 A1 7/2012 Ziegler et al.
2012/0185010 A1 7/2012 Zhou et al.
2012/0192874 A1 8/2012 Bolea et al.
2012/0271374 A1 10/2012 Nelson et al.
2012/0303080 A1 11/2012 Ben-David et al.
2013/0158616 A1 6/2013 Libbus et al.
2013/0158617 A1 6/2013 Libbus et al.
2013/0158618 A1 6/2013 Libbus et al.
2013/0238047 A1 9/2013 Libbus et al.
2013/0289646 A1 10/2013 Libbus et al.
2014/0025132 A1 1/2014 Libbus et al.
2014/0135862 A1 5/2014 Libbus et al.
2014/0135863 A1 5/2014 Libbus et al.
2014/0135864 A1 5/2014 Libbus et al.
2014/0228905 A1 8/2014 Bolea
2014/0277232 A1 9/2014 Libbus et al.
2015/0073512 A1 3/2015 Libbus et al.
2015/0094962 A1 4/2015 Hoegh et al.
2015/0119956 A1 4/2015 Libbus et al.
2015/0119959 A1 4/2015 Libbus et al.
2015/0196762 A1 7/2015 Amurthur et al.

OTHER PUBLICATIONS

PCT Application No. PCT/US2012/068205, Search Report and Written Opinion dated Feb. 8, 2013, 15 pages.
PCT Application No. PCT/US2012/068213, Search Report and Written Opinion dated Mar. 15, 2013, 11 pages.
PCT Application No. PCT/US2012/068223, Search Report and Written Opinion dated Apr. 3, 2013, 11 pages.
PCT Application No. PCT/US2013/021964, Search Report and Written Opinion dated Apr. 17, 2013, 10 pages.
PCT Application No. PCT/US2012/068211, Search Report and Written Opinion dated May 7, 2013, 9 pages.
PCT Application No. PCT/US2013/050390, Search Report and Written Opinion dated Nov. 5, 2013.
PCT Application No. PCT/US2013/068541, Search Report and Written Opinion dated Jan. 7, 2014.
Abraham, et al., "Devices in the management of advanced, chronic heart failure," Nature Reviews, vol. 10, pp. 98-110 (Feb. 2013) (Published online Dec. 11, 2012).
Adamson, et al., "Continuous Autonomic Assessment in Patients with Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device," Circulation, Journal of the American Heart Association, 110, pp. 2389-2394 (2004).
Agostoni, et al., "Functional and Histological Studies of the Vagus Nerve and its Branches to the Heart, Lungs and Abdominal Viscera in the Cat," J. Physiol. 135, pp. 182-205 (1957).
Ajani, et al., "Prevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values," Chemical Chemistry, 50:9, pp. 1618-1622 (2004).
Akiyama, et al., "Effects of right and left vagal stimulation on left ventricular acetylcholine levels in the cat," Acta Physiol Scand, 172, pp. 11-16 (2001).
Anand, et al., "C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan," Circulation, Journal of the American Heart Association, 112, pp. 1428-1434 (2005).

(56)

References Cited

OTHER PUBLICATIONS

- Anholt, et al., "Recruitment and blocking properties of the CardioFit stimulation lead," *Journal of Neural Engineering*, 8, pp. 1-6, (2011).
- Ardell, et al., "Selective vagal innervation of sinoatrial and atrioventricular nodes in canine heart," *Am. J. Physiol.* 251 (Heart Circ. Physiol. 20), pp. H764-H773 (1986).
- Armour, "Cardiac neuronal hierarchy in health and disease," *Am J Physiol Regul Integr Comp Physiol*, 287, pp. R262-R271 (2004).
- Armour, "Myocardial ischaemia and the cardiac nervous system," *Cardiovascular Research*, 41, pp. 41-54 (1999).
- Armour, JA, "Potential clinical relevance of the 'little brain' on the mammalian heart," *Experimental Physiology*, vol. 1 93, No. 2, pp. 165-176 (Feb. 2008). Online Publication Date: Nov 2, 2007. Available at: <http://ep.physoc.org/content/93/2/165.long>.
- Armour, "The little brain on the heart," *Cleveland Clinic Journal of Medicine*, vol. 74, supp. 1, pp. S48-S51 (Feb. 2007).
- Armour, et al., "Functional anatomy of canine cardiac nerves," *Acta anat.*, 91, pp. 510-528 (1975).
- Armour, et al., "Localized myocardial responses to stimulation of small cardiac branches of the vagus," *American Journal of Physiology*, vol. 228, No. 1 pp. 141-148 (Jan. 1975).
- Asala, et al., "An electron microscope study of vagus nerve composition in the ferret," *Anat Embryol*, 175, pp. 247-253 (1986).
- Aukrust, et al., "Inflammatory and anti-inflammatory cytokines in chronic heart failure: Potential therapeutic implications," *Annals of Medicine*, 37, pp. 74-85 (2005).
- Author Unknown, "Nerve fiber—Types and Function," www.boddunan.com Available at www.boddunan.com/education/20-medicine-a-surgery/12730-nerver-fiber-types-and-function.html (Apr. 19, 2010).
- Author Unknown, American Diabetes Association, "Standards of Medical Care in Diabetes—2012," *Diabetes Care*, vol. 35, supplement 1, pp. S11-S63 (Jan. 2012).
- Author Unknown, Staff of ADInstruments, "Principles of Nerve Stimulation," Application Note, ADInstruments (Apr. 2002).
- Bae, et al., "Gliosis in the Amygdala Following Myocardial Infarction in the Rat," *J Vet Med Sci*, 72(8), pp. 1041-1045 (2010).
- Bernik, et al., "Pharmacological Stimulation of the Cholinergic Antiinflammatory Pathway," *J. Exp. Med*, vol. 195, No. 6, pp. 781-788 (Mar. 18, 2002).
- Berthoud, et al., "Functional and chemical anatomy of the afferent vagal system," *Autonomic Neuroscience: Basic and Clinical*, 85, pp. 1-17 (2000).
- Bhagat, et al., "Differential Effect of Right and Left Vagal Stimulation on Right and Left Circumflex Coronary Arteries," *S A Medical Journal*, 50, pp. 1591-1594 (1976).
- Biasucci, et al., "Elevated Levels of C-Reactive Protein at Discharge in Patients with Unstable Angina Predict Recurrent Instability," *Circulation, Journal of the American Heart Association*, 99, pp. 855-860 (1999).
- Bibeovski, et al., "Evidence for impaired vagus nerve activity in heart failure," *Heart Fail Rev*, 16, pp. 129-135 (2011).
- Bibeovski, et al., "Ganglionic Mechanisms Contribute to Diminished Vagal Control in Heart Failure," *Circulation, Journal of the American Heart Association*, 99, pp. 2958-2963 (1999).
- Bilgutay, et al., "Vagal Tuning a new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure," *Journal of Thoracic and Cardiovascular Surgery*, vol. 56, No. 1, pp. 71-82 (Jul. 1968).
- Binkley, et al., "Parasympathetic Withdrawal is an Integral Component of Autonomic Imbalance in Congestive Heart Failure: Demonstration in Human Subjects and Verification in a Paced Canine Model of Ventricular Failure," *JACC*, vol. 18, No. 2, pp. 464-472 (Aug. 1991).
- Bois, et al., "Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells," *Abstract, British Journal of Pharmacology*, 118(4):1051-7 (1996).
- Bonaz, et al., "Vagus nerve stimulation: From epilepsy to the cholinergic anti-inflammatory pathway," *Neurogastroenterology & Motility*, pp. 1-14 (2013).
- Borggreffe, et al., "Vagal Stimulation Devices," ESC Congress 2010.
- Borovilkova, et al., "Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin," *Nature*, vol. 405, pp. 458-462 (May 25, 2000).
- Brack, et al., "Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation—tentative prophylactic properties in vagus nerve stimulation on malignant arrhythmias in heart failure," *Heart Fail Rev* (Published online Jun. 8, 2012).
- Bronzino, "Biomedical Engineering Fundamentals," CRC Press, Chapter 30, pp. 30-10-30-15 (Apr. 2006).
- Buschman, et al., "Heart Rate Control Via Vagus Nerve Stimulation," *Neuromodulation*, vol. 9, No. 3, pp. 214-220 (2006).
- Butterwick, et al., "Tissue Damage by Pulsed Electrical Stimulation," *IEEE Transactions on Biomedical Engineering*, vol. 54, No. 12, pp. 2261-2267 (Dec. 2007).
- Calkins, et al., "Comparison of Responses to Isoproterenol and Epinephrine During Head-Up Tilt in Suspected Vasodepressor Syncope," *The American Journal of Cardiology*, vol. 67 pp. 207-209 (Jan. 15, 1991).
- Castoro, et al., "Excitation properties of the right cervical vagus nerve in adult dogs," *Experimental Neurology*, 227 (pp. 62-68 (2011)).
- Chapleau, et al., "Methods of assessing vagus nerve activity and reflexes," *Heart Fail Rev*, 16, pp. 109-127 (2011).
- Chen, et al., "National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008," *JAMA*, vol. 306, No. 15 (Oct. 19, 2011).
- Chen, et al., "Role of Atrial Electrophysiology and Autonomic Nervous System in Patients with Supraventricular Tachycardia and Paroxysmal Atrial Fibrillation," *J Am Coll Cardiol*, vol. 32, No. 3, pp. 732-738 (Sep. 1998).
- Cheng, et al., "Long-term Outcomes in Individuals with Prolonged PR Interval or First-Degree Atrioventricular Block," *JAMA*, vol. 301, No. 24 pp. 2571-2577 (Jun. 24, 2009).
- Chiou, et al., "Effects of Continuous Enhanced Vagal Tone and Dual Atrioventricular Node and Accessory Pathways," *Circulation, Journal of the American Heart Association*, 107, pp. 2583-2588 (2003).
- Cohen, et al., "Histopathology of the stimulated Vagus nerve: Primum non nocere," *Heart Fail Rev*, 16, pp. 163-169 (2011).
- Colombo, et al., "Comparison between spectral analysis and the phenylephrine methods for the assessment of baroreflex sensitivity in chronic heart failure," *Clinical Science*, 97, pp. 503-513 (1999).
- Cryan, et al., "Animal models and mood disorders: recent developments," *Current Opinion in Psychiatry*, 20, pp. 1-7 (2007).
- Das, "Vagal nerve stimulation in prevention and management of coronary heart disease," *World J. Cardiol*, 3(4), pp. 105-110 (Apr. 26, 2011).
- De Castro, et al., "Parasympathetic-mediated atrial fibrillation during tilt test associated with increased baroreflex sensitivity," *The European Society of Cardiology, Europace*, 8, pp. 349-351 (2006).
- De Ferrari, et al., "Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients with Preserved Left Ventricular Function," *Journal of the American College of Cardiology*, vol. 50, No. 24, pp. 2285-2290 (2007).
- De Ferrari, et al., "Chronic Vagal Stimulation in Patients with Congestive Heart Failure," 31st Annual International Conference of the IEE EMBS (2009).
- De Ferrari, et al., "Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure," *European Heart Journal*, 32, pp. 847-855 (2011).
- De Ferrari, et al., "Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions," *Heart Fail Rev*, 16, pp. 195-203 (2011) (Published Online Dec. 17, 2010).
- De Jonge, et al., "Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway," *Nature Immunology*, vol. 6, No. 8, pp. 844-852 (Aug. 2005).
- Desai, et al., "Pharmacologic modulation of parasympathetic activity in heart failure," *Heart Fail Rev*, 16, pp. 179-193 (Published online: Oct. 6, 2010) (2011).
- Dickerson, et al., "Parasympathetic neurons in the cranial medial ventricular fat pad on the dog heart selectively decrease ventricular contractility," *Journal of the Autonomic Nervous System*, 70, pp. 129-141 (1998).

(56)

References Cited

OTHER PUBLICATIONS

- Dunlap, et al., "Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity," *Am J Physiol Heart Circ Physiol*, 285, pp. H1632-H1640 (Jun. 26, 2003).
- Elsenbruch, et al., "Heart Rate Variability During Waking and Sleep in Healthy Males and Females," *SLEEP*, vol. 22, No. 8, pp. 1067-1071 (1999).
- Euler, et al., "Acetylcholine release by a stimulus train lowers atrial fibrillation threshold," *Am. J Physiol.* 253 (Heart Circ. Physiol, 22), pp. H863-H868 (1987).
- Evans, et al., "Histological and functional studies on the fibre composition of the vagus nerve of the rabbit," *Journal of Anatomy*, 130, pp. 139-151 (1954).
- Fallen, "Vagal Afferent Stimulation as a Cardioprotective Strategy? Introducing the Concept," *A.N.E.*, vol. 10, No. 4 (Oct. 2005).
- Fan, et al., "Transvenous vagus nerve stimulation: A potential heart failure therapy is feasible in humans," *JACC*, vol. 55, issue 10A, pp. E152-E153 (2010).
- Fazan, et al., "Diabetic Peripheral Neuropathies: A Morphometric Overview," *Int. J. Morphol.*, 28(I), pp. 51-64 (2010).
- Feinauer, et al., "Ouabain enhances release of acetylcholine in the heart evoked by unilateral vagal stimulation," *Arch Pharmacol*, 333, pp. 7-12 (1986).
- Fonarow, et al., "Incremental Reduction in Risk of Death Associated with Use of Guideline-Recommended Therapies in Patients with Heart Failure: A Nested Case-Control Analysis of IMPROVE HF," *J Am Heart Assoc*, 1, pp. 16-26 (2012).
- Ford, et al., "The effects of electrical stimulation of myelinated and non-myelinated vagal fibres on heart rate in the rabbit," *J. Physiol.* 380, pp. 341-347 (1986).
- Furukawa, et al., "Effects of Verapamil, Zatebradine, and E-4031 on the Pacemaker Location and Rate in Response to Sympathetic Stimulation in Dog Hearts," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 289, No. 3, pp. 1334-1342 (1999).
- Furukawa, et al., "Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs," Abstract, *Journal of Pharmacology & Experimental Therapeutics*, 272(2):744-9 (1995).
- Gatti, et al., "Can neurons in the nucleus ambiguus selectively regulate cardiac rate and atrio-ventricular conduction?" *Journal of The Autonomic Nervous System*, 57, pp. 123-127 (1996).
- Gatti, et al., "Vagal control of left ventricular contractility is selectively mediated by a cranioventricular intracardiac ganglion in the cat," *Journal of the Autonomic Nervous System*, 66, pp. 138-144 (1997).
- Gibbons, et al., "Neuromodulation targets intrinsic cardiac neurons to attenuate neuronally mediated atrial arrhythmias," *Am J Physiol Regul Integr Comp Physiol* 302: R357-R364 (2012) (First published Nov. 16, 2011).
- Gottdiener, et al., "Predictors of Congestive Heart Failure in the Elderly: The Cardiovascular Health Study," *Journal of the American College of Cardiology*, vol. 35, No. 6, pp. 1628-1637 (2000).
- Gray, et al., "Parasympathetic control of the Heart. II. A novel interganglionic intrinsic cardiac circuit mediates neural control of heart rate," *J. Appl Physiol*, 96, pp. 2273-2278 (2004).
- Gray, et al., "Parasympathetic control of the Heart. III. Neuropeptide Y-immunoreactive nerve terminals synapse on three populations of negative chronotropic vagal preganglionic neurons," *J. Appl Physiol*, 96, pp. 2279-2287 (2004).
- Grill, "Chapter 14—Principles of Electric Field Generation for Stimulation of the Central Nervous System," *Neuromodulation*, Academic Press (2009).
- Guilleminault, et al., "Cyclical Variation of the Heart Rate in Sleep Apnoea Syndrome," *The Lancet*, pp. 126-131 (Jan. 21, 1984).
- Hardwick, et al., "Chronic myocardial infarction induces phenotypic and functional remodeling in the guinea pig cardiac plexus," *Am J Physiol Regulatory Integrative Comp Physiol*, 295, pp. 1926-1933 (2008).
- Hardwick, et al., "Remodeling of the guinea pig intrinsic cardiac plexus with chronic pressure overload," *Am J Physiol Regulatory Integrative Comp Physiol*, 297, pp. 859-866 (2009).
- Hauptman, et al., "The vagus nerve and autonomic imbalance in heart failure: past, present, and future," *Heart Fail Rev*, 16, pp. 97-99 (2011).
- Hellyer, et al., "Autonomic nerve activity and blood pressure in ambulatory dogs," *Heart Rhythm*, vol. 11(2), pp. 307-313 (Feb. 2014).
- Hirooka, et al., "Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension," *Am J Physiol Regulatory Integration Comp Physiol*, 300, pp. 818-826 (2011).
- Hoffman, et al., "Vagus Nerve Components," *Anat Rec*, 127, pp. 551-568 (1957).
- Hu, et al., "Role of sympathetic nervous system in myocardial ischemia injury: Beneficial or deleterious?" *Letters to the Editor*, Elsevier Ireland Ltd. (Mar. 27, 2012).
- Hua, et al., "Left vagal stimulation induces dynorphin release and suppresses substance P release from the rat thoracic spinal cord during cardiac ischemia," *Am J Physiol Regulatory Integration Comp Physiol*, 287, pp. 1468-1477 (2004).
- Huston, et al., "Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis," *J. Exp. Med.*, vol. 203, No. 7 pp. 1623-1628 (Jun. 19, 2006).
- Huston, et al., "Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis," *Crit Care Med*, vol. 35, No. 12, pp. 2762-2768 (2007).
- Ingemansson, et al., "Autonomic modulation of the atrial cycle length by the head up tilt test: non-invasive evaluation in patients with chronic atrial fibrillation," *Heart*, 80, pp. 71-76 (1998).
- Ito, et al., "Efferent sympathetic and vagal innervation of the canine right ventricle," *Circulation, Journal of the American Heart Association*, vol. 90, pp. 1469-1468 (1994).
- Jacques, et al., "Spinal Cord Stimulation Causes Potentiation of Right Vagus Nerve Effects on Atrial Chronotropic Function and Repolarization in Canines," *Journal of Cardiovascular Electrophysiology*, vol. 22, No. 4, pp. 440-447 (Apr. 2011).
- Jaenisch, et al., "Respiratory muscle training improves baroreceptor sensitivity, decrease sympathetic tonus and increase vagal effect in rats with heart failure," *European Heart Journal*, 32 (Abstract Supplement, pp. 976 (2011).
- Jammes, et al., "Afferent and efferent components of the bronchial vagal branches in cats," *Journal of the Autonomic Nervous System*, 5, pp. 165-176 (1982).
- Janabi, et al., "Oxidized LDL—Induced NF-kB Activation and Subsequent Expression of Proinflammatory Genes are Defective in Monocyte-Derived Macrophages from CD36-Deficient Patients," *Arterioscler Thromb Vasc Biol.*, 20:1953-1960 (2000).
- Janse, et al., "Effects of unilateral stellate ganglion stimulation and ablation on electrophysiologic changes induced by acute myocardial ischemia in dogs," *Circulation, Journal of the American Heart Association*, 72, pp. 585-595 (1985).
- Jessup, et al., "2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults," *Circulation, Journal of the American Heart Association*, vol. 119, pp. 1977-2016 (2009).
- Johnson, et al., "Parasympathetic control of the heart. I. An interventriculo-septal ganglion is the major source of the vagal intracardiac innervation of the ventricles," *J Appl Physiol*, 96, pp. 2265-2272 (2004).
- Kakinuma, et al., "Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium," *FEBS Journal*, 276, pp. 5111-5125 (2009).
- Kalman, "Specific effects of zatebradine on sinus node function: suppression of automaticity, prolongation of sinoatrial conduction and pacemaker shift in the denervated canine heart," Abstract, *Journal of Pharmacology & Experimental Therapeutics*, 272(1):85-93 (1995).
- Kaneko, et al., "C-Reactive Protein in Dilated Cardiomyopathy," *Cardiology*, 91, pp. 215-219 (1999).

(56)

References Cited

OTHER PUBLICATIONS

- Katare, et al., "Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of bradycardiac effect," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 137, No. 1, pp. 223-231 (2009).
- Katz, et al., "Diseases of the heart in the Works of Hippocrates," *Br Heart J*, 24, pp. 257-264 (1962).
- Kawada, et al., "High-frequency dominant depression of peripheral vagal control of heart rate in rats with chronic heart failure," *Acta Physiol* 207, 494-502 (2013).
- Kawada, et al., "Vagal stimulation suppresses ischemia-induced myocardial interstitial norepinephrine release," *Life Sciences*, 78, pp. 882-887 (2006).
- Kawashima, "The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution," *Anat Embryol*, 209, pp. 425-438 (2005).
- Klein et al., "Vagus nerve stimulation: A new approach to reduce heart failure," *Cardiology Journal*, vol. 17, iss. 6, pp. 638-643 (2010).
- Kliks, et al., "Influence of Sympathetic Tone on Ventricular Fibrillation Threshold During Experimental Coronary Occlusion," *The American Journal of Cardiology*, vol. 36, pp. 45-49 (Jul. 1975).
- Kolman, et al., "The effect of vagus nerve stimulation upon vulnerability of the canine ventricle: role of sympathetic-parasympathetic interactions," *Journal of the American Heart Association*, 52, pp. 578-585 (1975).
- Kong, et al., "Optimizing the Parameters of Vagus Nerve Stimulation by Uniform Design in Rats with Acute Myocardial Infarction," *PLOS One*, vol. 7, issue 11 (Nov. 2012).
- Koopman, et al., "Pilot study of stimulation of the cholinergic anti-inflammatory pathway with an implantable vagus nerve stimulation device in patients with rheumatoid arthritis," *Abstract* (2010).
- Kulbertus, et al., ed., "Neurocardiology," Futura Publishing Co., pp. 13 ("Anatomy of the Cardiac Efferent Innervation"); 61-63 ("Autonomic Neural Control"); 87, 89, 92-93 ("Sympathetic-Parasympathetic Interactions"); 183, 187 ("Parasympathetic Nervous System"); 104 (1988).
- La Rovere, et al., "Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias: Implications for Clinical Trials," *Circulation Journal of the American Heart Association*, 103, pp. 2072-2077 (2001).
- La Rovere, et al., "Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators," *Lancet*, 351(9101), pp. 478-484 (Feb. 14, 1998).
- Lane, et al., "Prediction and Prevention of Sudden Cardiac Death in Heart Failure," *Heart*, 91, pp. 674-680 (2005).
- Lechat, et al., "Heart rate and Cardiac Rhythm Relationships with Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial," *Circulation, Journal of American Heart Association*, 103, pp. 1428-1433 (2001).
- Lewis, et al., "Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart," *Journal of Physiology*, 534, pp. 547-552 (2001).
- Li, et al., "Early vagal stimulation markedly prevented cardiac dysfunction in rats after acute myocardial infarction in addition to suppressing arrhythmic death," *European Heart Journal*, 32 (Abstract Supplement), pp. 297-298 (2011).
- Li, et al., "Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation," *Heart Fail Rev*, 16, pp. 137-145 (2011).
- Li, et al., "Low-Level Vagosympathetic Stimulation. A Paradox and Potential New Modality for the Treatment of Focal Atrial Fibrillation," *Circ Arrhythm Electrophysiol, Journal of American Heart Association*, 2, pp. 645-651 (2009).
- Li, et al., "Restoration of vagal tone by donepezil, on top of losartan treatment, markedly suppresses ventricular dysfunction and improves long-term survival in chronic heart failure rats," *European Heart Journal*, 32 (Abstract Supplement), pp. 642 (2011).
- Li et al., "Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats," *Circulation: Journal of the American Heart Association*, vol. 109, iss. 1, pp. 120-124 (Jan. 2004). Online publication date: Dec. 8, 2003.
- Libby, et al., "Inflammation and Atherosclerosis," *Circulation, Journal of the American Heart Association*, 105, pp. 1135-1143 (2002).
- Liu, et al., "Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity," *Am. J. Physiol.* 273 (Heart Circ. Physiol. 42), pp. H805-H816 (1997).
- Lo, et al., "Paradoxical long-term proarrhythmic effects after ablating the 'head station' ganglionated plexi of the vagal innervation to the heart," *Heart Rhythm*, vol. 10, No. 5, pp. 751-757 (May 2013).
- Lohmeier, et al., "Prolonged Activation of the Baroreflex Produces Sustained Hypotension," *Hypertension, Journal of the American Heart Association*, 43, pp. 306-311 (2004).
- Lu, et al., "Vagal nerve stimulation protects cardiac injury by attenuating mitochondrial dysfunction in a murine burn injury model," *J. Cell. Mol. Med.*, vol. 17, No. 5, pp. 664-671 (2013).
- Ma, et al., "Analysis of afferent, central, and efferent components of the baroreceptor reflex in mice," *Am J Physiol Regulatory Integration Comp Physiol*, 283, pp. 1033-1040 (2002).
- Maj, et al., "P5775: Autonomic imbalance and circulating androgens and estrogens in men with systolic heart failure," *European Heart Journal*, 32 (Abstract Supplement), pp. 1090 (2011).
- Malkin, et al., "Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart failure," *The European Journal of Heart Failure*, 7, pp. 143-148 (2005).
- Mann, "Chapter 12—Peripheral Nerves," *The Nervous System in Action*, michaeldmann.net/mann12.html, (Jul. 2011).
- Mann, "Inflammatory Mediators and the Failing Heart. Past, Present, and the Foreseeable Future," *Circ Res.*, 91, pp. 988-998 (2002).
- Mann, "Stress-Activated Cytokines and the Heart: From Adaptation to Maladaptation," *Annu. Rev. Physiol.*, 65, pp. 81-101 (2003).
- Martin-Portugues, et al., "Histopathologic features of the vagus nerve after electrical stimulation in swine," *Histol Histopathol*, 20, pp. 851-856 (2005).
- Martins, et al., "Distribution of Local Repolarization Changes Produced by Efferent Vagal Stimulation in the Canine Ventricles," *JACC*, vol. 2, No. 6, pp. 1191-9119 (Dec. 1983).
- Massari, et al., "Neural control of left ventricular contractility in the dog heart: synaptic interactions of negative inotropic vagal preganglionic neurons in the nucleus ambiguus and tyrosine hydroxylase immunoreactive terminals," *Brain Research*, 802, pp. 205-220 (1998).
- May, et al., "P564: Long-term prediction of all-cause mortality in diabetic autonomic neuropathy: simple function tests or 24-hour heart rate variability (HRV)?" *European Heart Journal*, 32 (Abstract Supplement), pp. 64 (2011).
- Mei, et al., "The Composition of the Vagus Nerve of the Cat," *Cell Tissue Res.*, 209, pp. 423-431 (1980).
- Merrill, et al., "Electrical stimulation of excitable tissue: design of efficacious and safe protocols," *Journal of Neuroscience Methods*, 141, pp. 171-198 (2005).
- Mortara, et al., "Arterial Baroreflex Modulation of Heart Rate in Chronic Heart Failure," *Circulation, Journal of the American Heart Association*, vol. 96, No. 10, pp. 3450-3458 (Nov. 18, 1997).
- Murakawa, et al., "Effect of Cervical Vagal Nerve Stimulation on Defibrillation Energy," *Jpn Heart J*, 44, pp. 91-100 (Jan. 2003).
- Naito, "Effects of zatebradine and propranolol on canine ischemia and reperfusion-induced arrhythmias," *European Journal of Pharmacology*, 388, pp. 171-176 (2000).
- Nakajima, et al., "Autonomic Control of the Location and Rate of the Cardiac Pacemaker in the Sinoatrial Fat Pad of Parasympathetically Denervated Dog Hearts," *Journal of Cardiovascular Electrophysiology*, vol. 13, No. 9 pp. 896-901 (Sep. 2002).
- Nearing, et al., "Crescendo in Depolarization and Repolarization Heterogeneity Heralds Development of Ventricular Tachycardia in Hospitalized Patients with Decompensated Heart Failure," *Circulation Arrhythmia and Electrophysiology, Journal of the American Heart Association*, 5, pp. 84-90 (2012).
- Ninei, et al., "Decreased Vagal Control Over Heart Rate in Rats with Right-Sided Congestive Heart Failure—Downregulation of Neuronal Nitric Oxide Synthase," *Circ J*, 69, pp. 493-499 (2005).

(56)

References Cited

OTHER PUBLICATIONS

- Ninomiya, "Direct Evidence of Nonuniform Distribution of Vagal Effects on Dog Atria," *Circulation Research*, vol. XIX, pp. 576-583 (Sep. 1966).
- Nolan, et al., "Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure: Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart)," *Circulation, Journal of the American Heart Association*, 98, pp. 1510-1516 (1998).
- Ochoa, et al., "P2497: Effects of insulin resistance on resting heart rate, baroreflex sensitivity and indices of autonomic cardiovascular modulation in individuals with high blood pressure levels," *European Heart Journal*, 32 (Abstract Supplement, pp. 431-432 (2011).
- Ogawa, et al., "Left Stellate Ganglion and Vagal Nerve Activity and Cardiac Arrhythmias in Ambulatory Dogs with Pacing-Induced Congestive Heart Failure," *Journal of the American College of Cardiology*, vol. 50, No. 4, pp. 335-444 (2007).
- Okada, et al., "Cyclic Stretch Upregulates Production of Interleukin-8 and Monocyte Chemoattractant and Activating Factor/Monocyte Chemoattractant Protein-1 in Human Endothelial Cells," *Arterioscler Thromb Vasc Biol.*, 18, pp. 894-901 (1998).
- Oliveira, et al., "Effects of vagal stimulation on induction and termination of atrial fibrillation in an in vivo rabbit heart model," *Rev Port Cardiol*, 29(03), pp. 375-389 (2010).
- Olshansky, et al., "Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy," *Circulation, Journal of the American Heart Association*, 118, pp. 863-871 (2008).
- Onkka, et al., "Sympathetic nerve fibers and ganglia in canine cervical vagus nerves: Localization and quantitation," *Heart Rhythm*, vol. 10, No. 4, pp. 585-591 (Apr. 2013).
- Ordelman, et al., "Selectivity for Specific Cardiovascular Effects of Vagal Nerve Stimulation with a Multi-Contact Electrode Cuff," *IEEE*, pp. 1-6 (2011).
- Packer, et al., "Effect of Carvedilol on Survival in Severe Chronic Heart Failure," *The New England Journal of Medicine*, vol. 344, No. 22, pp. 1651-1658 (May 31, 2001).
- Pavlov, et al., "Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia," *PNAS*, vol. 103, No. 13, pp. 5219-5223 (Mar. 28, 2006).
- Pavlov, et al., "Controlling inflammation: the cholinergic anti-inflammatory pathway," *Biochemical Society Transactions*, vol. 34, part 6, pp. 1037-1040 (2006).
- Peckham, et al., "Chapter 18—Implantable Neural Stimulators," *Neuromodulation*, Academic Press (2009).
- Pina, et al., "The Predictive Value of Biomarkers in Heart Failure," *Medscape Education Cardiology*, Available at <http://www.medscape.org/viewarticle/765328> (CME Released: Jun. 15, 2012).
- Pitzalis, et al., "Comparison Between Noninvasive Indices of Baroreceptor Sensitivity and the Phenylephrine Method in Post-Myocardial Infarction Patients," *Circulation, Journal of the American Heart Association*, 97, pp. 1362-1367 (1998).
- Poole-Wilson, "Relation of Pathophysiologic Mechanisms to Outcome in Heart Failure," *JACC*, vol. 22, No. 4 (supplement A), pp. 22A-29A (Oct. 1993).
- Pye, et al., "Study of serum C-reactive protein concentration in cardiac failure," *Br Heart J*, 63, pp. 228-230 (1990).
- Rademacher, et al., "P5878: Multidimensional holter-based analysis of cardiac autonomic regulation predicts early AF recurrence after electrical cardioversion," *European Heart Journal*, 32 (Abstract Supplement), pp. 1116-1117 (2011).
- Randall, et al., "Regional vagosympathetic control of the heart," *American Journal of Physiology*, vol. 227, No. 2, pp. 444-452 (1974).
- Randall, et al., "Selective Vagal Innervation of the Heart," *Annals of Clinical and Laboratory Science*, vol. 16, No. 3, pp. 198-208 (1986).
- Raymond, et al., "Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction," *American Heart Journal*, vol. 141, No. 3, pp. 435-438 (Mar. 2001).
- Rhee, et al., "Effects of suprathreshold vagal stimulation on stellate ganglion nerve activity in ambulatory dogs," 33rd Annual Scientific Sessions, Heart Rhythm, Presentation Abstract (2012).
- Riccio, et al., "Interganglionic segregation of distinct vagal afferent fibre phenotypes in guinea-pig airways," *Journal of Physiology*, 495, 2, pp. 521-530 (1996).
- Riddle, et al., "Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial," *Diabetes Care*, vol. 33, No. 5, pp. 983-990 (May 2010).
- Ridker, "C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke," *Journal of the American Heart Association*, 108, pp. e81-e85 (2003).
- Ridker, et al., "Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events," *New England Journal of Medicine*, vol. 347, No. 20, pp. 1557-1566 (Nov. 14, 2002).
- Ridker, et al., "C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women," *The New England Journal of Medicine*, vol. 342, No. 12, pp. 836-841 (Mar. 23, 2000).
- Ridker, et al., "Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels," *Circulation, Journal of the American Heart Association*, 98, pp. 839-844 (1998).
- Roger, et al., "Heart Disease and Stroke Statistics-2011 Update: A Report from the American Heart Association," *Circulation, Journal of the American Available at <http://circ.ahajournals.org/content/123/4/e18>* (2010).
- Romanovsky, et al., "The vagus nerve in the thermoregulatory response to systemic inflammation," *Am. J. Physiol.*, 273, pp. R407-R413 (1997).
- Rossi, et al., "Epicardial ganglionated plexus stimulation decreases postoperative inflammatory response in humans," *Heart Rhythm*, vol. 9, No. 6, pp. 943-950 (Jun. 2012).
- Rouse, et al., "The haemodynamic actions of ZENCA ZD7288, a novel sino-atrial node function modulator, in the exercising beagle: a comparison with zategradine and propranolol," *Abstract, British Journal of Pharmacology*, 113(3):1071-7 (1994).
- Rozman, et al., "Heart function influenced by selective mid-cervical left vagus nerve stimulation in a human case study," *Hypertension Research*, 32, pp. 1041-1043 (2009).
- Rutecki, "Anatomical, Physiological and Theoretical Basis for the Antiepileptic Effect of Vagus Nerve Stimulation," *Epilepsia*, 31 (suppl. 2), pp. S1-S6 (1990).
- Sabbah, et al., "3722: Vagus nerve stimulation improves left ventricular function in heart failure: results of a 6 month investigation with a cross-over design in dogs with experimental heart failure," *European Heart Journal*, 32 (Abstract Supplement), pp. 642 (2011).
- Sabbah, et al., "Baroreflex Activation Therapy for the Treatment of Heart Failure," Presentation available at <http://www.cvr.com/wp/wp-content/uploads/2012/04/Dr.-Sabbah-Slides.pdf> (2012).
- Sabbah, et al., "Chronic Electrical Stimulation of the Carotid Sinus Baroreflex Improves Left Ventricular Function and Promotes Reversal of Ventricular Remodeling in Dogs with Advanced Heart Failure," *Circulation Heart Failure, Journal of the American Heart Association*, 4, pp. 65-70 (2011).
- Sabbah et al., "Vagus nerve stimulation in experimental heart failure," *Heart Failure Reviews*, vol. 16, No. 2, pp. 171-178 (Mar. 2011). Online Publication Date: Dec. 3, 2010.
- Samara, et al., "The Effects of Cardiac Resynchronization Therapy on Chronotropic Incompetence in Patients Intolerant of Beta Antagonist Therapy," *Journal of Cardiac Failure*, vol. 17, No. 8S, pp. S-54-S55 (Aug. 2011).
- Sanner, et al., "P4743: Prediction of cardiovascular risk from nocturnal pulse wave signal using the autonomic state indicator (ASI) technology," *European Heart Journal*, 32 (Abstract Supplement), pp. 839 (2011).
- Sato, et al., "Serial Circulating Concentrations of C-Reactive Protein, Interleukin (IL)-4, and IL-6 in Patients with Acute Left Heart Decompensation," *Clin. Cardiol.* 22, pp. 811-813 (1999).

(56)

References Cited

OTHER PUBLICATIONS

- Schauerte, "Time for Change: Cardiac neurophysiology meets cardiac electrophysiology," Editorial Commentary, *Heart Rhythm Society* (2013).
- Schiereck, et al., "AV blocking due to asynchronous vagal stimulation in rats," *Am J Physiol Heart Circ Physiol*, 278, pp. H67-H73 (2000).
- Schocken, et al., "Prevalence and Mortality Rate of Congestive Heart Failure in the United States," *JACC*, vol. 20, No. 2, pp. 301-306 (Aug. 1992).
- Schwartz, "Vagal Stimulation for Heart Diseases: From Animals to Men," *Circulation Journal*, vol. 75, pp. 20-27 (Jan. 2011).
- Schwartz, "Vagal stimulation for heart failure," *Current Opinion in Cardiology*, 26, pp. 51-54 (2011).
- Schwartz, "Vagal stimulation for the treatment of heart failure: a translational success story," *Heart*, vol. 98, No. 23, pp. 1687-1690 (2012).
- Schwartz, et al. Vagal stimulation for heart failure: Background and first in-man study, *Heart Rhythm*, 6, 11 suppl., pp. S76-S81 (Nov. 2009).
- Schwartz, et al., "Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without myocardial infarction," *Circulation*, *Journal of the American Heart Association*, 78, pp. 969-979 (1988).
- Schwartz, et al., "Effects of Unilateral Cardiac Sympathetic Denervation on the Ventricular Fibrillation Threshold," *The American Journal of Cardiology*, vol. 37, pp. 1034-1040 (Jun. 1976).
- Schwartz, et al., "Long term vagal stimulation in patients with advanced heart failure. First experience in man," *European Journal of Heart Failure*, 10, pp. 884-891 (2008).
- Schwartz, et al., "Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure," *Heart Fail Rev*, 16, pp. 101-107 (2011).
- Seta, et al., "Basic Mechanisms in Heart Failure: The Cytokine Hypothesis," *Journal of Cardiac Failure*, vol. 2, No. 3, pp. 243-249 (1996).
- Sha, et al., "Low-Level Right Vagal Stimulation: Anticholinergic and Antiadrenergic Effects," *J Cardiovasc Electrophysiol*, pp. 1-7 (Feb. 2011).
- Shamoon, et al., The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus," *The New England Journal of Medicine*, vol. 329, No. 14, pp. 977-986 (Sep. 30, 1993).
- Shannon, "A Model of Safe Levels for Electrical Stimulation," *IEEE Transactions on Biomedical Engineering*, vol. 39, No. 4, pp. 424-426 (Apr. 1992).
- Shen, et al., "Continuous Low-Level Vagus Nerve Stimulation Reduces Stellate Ganglion Nerve Activity and Paroxysmal Atrial Tachyarrhythmias in Ambulatory Canines," *Circulation*, *Journal of the American Heart Association*, 123, pp. 2204-2212 (2011).
- Shen, et al., "Low-level vagus nerve stimulation upregulates small conductance calcium-activated potassium channels in the stellate ganglion," *Heart Rhythm*, vol. 10, No. 6, pp. 910-915 (2013).
- Shinohara, et al., "Heart Failure Decreases Nerve Activity in the Right Atrial Ganglionated Plexus," *J Cardiovasc Electrophysiol*, pp. 1-9 (2011).
- Shioi, et al., "Increased Expression of Interleukin-1B and Monocyte Chemoattractant and Activating Factor/Monocyte Chemoattractant Protein-1 in the Hypertrophied and Failing Heart with Pressure Overload," *Circ Res.*, 81, pp. 664-671 (1997).
- Singal, et al., "The role of oxidative stress in the genesis of heart disease," *Cardiovascular Research*, 40, pp. 426-432 (1998).
- Spuck, et al., "Right-sided vagus nerve stimulation in humans: An effective therapy?" *Epilepsy Research*, pp. 1-3 (2008).
- Stein, et al., "A Simple Method to Identify Sleep Apnea Using Holter Recordings," *J Cardiovasc Electrophysiol*, vol. 14, pp. 467-473 (May 2003).
- Stein, et al., "Feasibility of Using Mobile Cardiac Outpatient Telemetry (MCOT) to Identify Severe Sleep Disorders" (2009).
- Stieber, et al., "Bradycardic and proarrhythmic properties of sinus node inhibitors," *Abstract, Molecular Pharmacology*, 69(4):1328-37 (2006).
- Taylor, et al., "The unequal influences of the left and right vagi on the control of the heart and pulmonary artery in the rattlesnake, *Crotalus durissus*," *The Journal of Experimental Biology*, 212, pp. 145-151 (2009).
- Thayer, et al., "The role of vagal function in the risk for cardiovascular disease and mortality," *Biological Psychology*, 74, pp. 224-242 (2007).
- Thollon, et al., "Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49," *Abstract, British Journal of Pharmacology*, 112(1):37-42 (1994).
- Tosato, et al., "Quasi-trapezoidal pulses to selectively block the activation of intrinsic laryngeal muscles during vagal nerve stimulation," *J. Neural Eng.*, 4, pp. 205-212 (2007).
- Tsutsumi, et al., "Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction," *Cardiovascular Research*, 77, pp. 713-721 (2008).
- Tyler, et al., "Chapter 17—Electrodes for the Neural Interface," *Neuromodulation*, Academic Press (2009).
- Ulphani, et al., "Quantitative analysis of parasympathetic innervation of the porcine heart," *Heart Rhythm*, 7, pp. 1113-1119 (2010).
- Uthman, et al., "Effectiveness of vagus nerve stimulation in epilepsy patients. A 12-year observation," *Neurology*, 63, pp. 1124-1126 (2004).
- Van Stee, "Autonomic Innervation of the Heart," *Environmental Health Perspectives*, vol. 26, pp. 151-158 (1978).
- Vanoli, et al., "Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction," *Circulation Research*, *Journal of the American Heart Association*, 68, pp. 1471-1481 (1991).
- Vasan, et al., "Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction," *Circulation*, *Journal of the American Heart Association*, 107, pp. 1486-1491 (2003).
- Vassalle, et al., "An Analysis of Arrhythmias Induced by Ouabain in Intact Dogs," *Circulation Research*, *Journal of the American Heart Association*, 13, pp. 132-148 (1963).
- Velagaleti, et al., "Long-Term Trends in the Incidence of heart Failure After Myocardial Infarction," 118, pp. 2057-2062 (2008).
- Verrier, et al., "Microvolt T-Wave Alternans," *Journal of the American College of Cardiology*, vol. 58, No. 13, pp. 1309-1324 (2011).
- Vimercati, et al., "Acute vagal stimulation attenuates cardiac metabolic response to B-adrenergic stress," *The Journal of Physiology*, vol. 500, No. 23, pp. 6065-6074 (2012).
- Wang, et al., "Nicotinic acetylcholine receptor alpha-7 subunit is an essential regulator of inflammation," *Nature*, vol. 421, pp. 384-388 (Jan. 23, 2003).
- Wang, et al., "Synaptic and Neurotransmitter Activation of Cardiac Vagal Neurons in the Nucleus Ambiguus," *Annals New York Academy of Sciences*, pp. 237-246 (2001).
- Waninger, et al., "Characterization of Atrioventricular Nodal Response to Electrical Left Vagal Stimulation," *Annals of Biomedical Engineering*, vol. 27, pp. 758-762 (1999).
- Wann, "Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline," *Journal of Psychopharmacology*, 23(4), pp. 451-459 (2009).
- Wann, et al., "Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depression," *J Psychiatry Neurosci*, 32(1):11-6, pp. 11-16 (2007).
- Watkins, et al., "Cytokine-to-Brain Communication: A Review & Analysis of Alternative Mechanisms," *Life Sciences*, vol. 57, No. 11, pp. 1011-1026 (1995).
- Whyte, et al., "Reactive oxygen species modulate neuronal excitability in rat intrinsic cardiac ganglia," *Auton Neurosci*, 150(1-2), pp. 45-52 (Oct. 5, 2009).
- Yang, et al., "Sustained increases in heart rate induced by time repetition of vagal stimulation in dogs," *Am. J. Physiol.*, 249, pp. H703-H709 (1985).

(56)

References Cited

OTHER PUBLICATIONS

Yin, et al., "Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure," *American Heart Journal*, vol. 147, No. 5, pp. 931-938 (2004).

Yndestad, et al., "Systemic inflammation in heart failure—The whys and wherefores," *Heart Fail Rev*, 11, pp. 83-92 (2006).

Yoo, et al., "High-resolution measurement of electrically-evoked vagus nerve activity in the anesthetized dog," *J. Neural Eng.*, 10, pp. 1-9 (2013).

Yoo, et al., "Selective Control of Physiological Responses by Temporally-Patterned Electrical Stimulation of the Canine Vagus Nerve," 33rd Annual International Conference of the IEEE EMBS (2011).

Yu, et al., "Interactions between atrial electrical remodeling and autonomic remodeling: How to break the vicious cycle," *Heart Rhythm*, 9, pp. 804-809 (2012).

Yu, et al., "Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: A noninvasive approach to treat the initial phase of atrial fibrillation," *Heart Rhythm*, 10, pp. 428-435 (2013).

Yuan, et al., "Gross and Microscopic Anatomy of the Canine Intrinsic Cardiac Nervous System," *The Anatomical Record*, 239, pp. 75-87 (1994).

Yusuf, et al., "Changes in Hypertension Treatment and in Congestive Heart Failure Mortality in the United States," *Hypertension, Journal of the American Heart Association*, 13:174-1179 (1989).

Zhang, et al., "Arrhythmias and vagus nerve stimulation," *Heart Fail Rev*, 16, pp. 147-161 (2011).

Zhang, et al., "Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing Model," *Journal of the American Heart Association, Circ Heart Fail*, 2, pp. 692-699 (2009).

Zhang, et al., "Involvement of activated astrocyte and microglia of locus coeruleus in cardiac pain processing after acute cardiac injury," *Neuro Res*, 31, pp. 432-438 (2009).

Zhang, et al., "Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: Therapeutic intensities do not increase arrhythmogenesis," *Heart Rythm*, 6, pp. 244-250 (2009).

Zhang, et al., "Therapeutic Effects of Selective Atrioventricular Node Vagal Stimulation in Atrial Fibrillation and Heart Failure," *Journal of Cardiovascular Electrophysiology*, vol. 24, Issue 1, pp. 86-91 (2012).

Zheng, et al., "Vagal stimulation markedly suppresses arrhythmias in conscious rats with chronic heart failure after myocardial infarction," *Proceedings of the 2005 IEEE* (2005).

Zipes, et al., "Effects of selective vagal and stellate ganglion stimulation on atrial refractoriness," *Cardiovascular Research*, 8, pp. 647-655 (1974).

Zucker, et al., "Chronic Baroreceptor Activation Enhances Survival in Dogs with Pacing-Induced Heart Failure," *Journal of the American Heart Association, Hypertension* (2007).

PCT Application No. PCT/US2014/024827, Search Report and Written Opinion dated Nov. 11, 2014, 18 pages.

PCT Application No. PCT/US2013/068541, International Preliminary Report on Patentability dated May 21, 2015, 9 pages.

* cited by examiner




Fig. 2A.




Fig. 2B.




Fig. 3.




Fig. 4.




Fig. 5.




Fig. 6.




Fig. 7.





Fig. 8.

110



1

**IMPLANTABLE
NEUROSTIMULATOR-IMPLEMENTED
METHOD FOR ENHANCING HEART
FAILURE PATIENT AWAKENING THROUGH
VAGUS NERVE STIMULATION**

CROSS REFERENCE TO RELATED
APPLICATION

This patent application is a continuation of U.S. patent application Ser. No. 13/673,811, filed Nov. 9, 2012, now U.S. Pat. No. 8,923,964, the priority of which is claimed and the disclosure of which is incorporated by reference in its entirety.

FIELD

This application relates in general to chronic cardiac dysfunction therapy and, in particular, to an implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation.

BACKGROUND

Congestive heart failure (CHF) and other forms of chronic cardiac dysfunction (CCD) are generally attributed to an autonomic imbalance of the sympathetic and parasympathetic nervous systems that, if left untreated, can lead to cardiac arrhythmogenesis, progressively worsening cardiac function and eventual patient death. CHF is pathologically characterized by an elevated neuroexcitatory state and is accompanied by physiological indications of impaired arterial and cardiopulmonary baroreflex function with reduced vagal activity.

CHF triggers compensatory activations of the sympathoadrenal (sympathetic) nervous system and the renin-angiotensin-aldosterone hormonal system, which initially help to compensate for deteriorating heart-pumping function, yet, over time, can promote progressive left ventricular dysfunction and deleterious cardiac remodeling. Patients suffering from CHF are at increased risk of tachyarrhythmias, such as atrial fibrillation (AF), ventricular tachyarrhythmias (ventricular tachycardia (VT) and ventricular fibrillation (VF)), and atrial flutter, particularly when the underlying morbidity is a form of coronary artery disease, cardiomyopathy, mitral valve prolapse, or other valvular heart disease. Sympathoadrenal activation also significantly increases the risk and severity of tachyarrhythmias due to neuronal action of the sympathetic nerve fibers in, on, or around the heart and through the release of epinephrine (adrenaline), which can exacerbate an already-elevated heart rate.

The increased risk of tachyarrhythmias, particularly VT, in CHF patients is seen during the three-hour period following awakening from sleep, which is accompanied by a 2.5 times higher incidence of mortality. Tachyarrhythmias during awakening have been linked to a sympathetic activity surge that naturally occurs whenever a person is waking up as a part of the natural human circadian rhythm cycle. Sleep is characterized by the predominance of the parasympathetic system and a withdrawal of sympathetic activity, followed by a peak of sympathetic activity upon a person assuming an upright position and increasing activity level upon awakening. The surge of sympathetic activity increases heart rate, which in turn makes a CHF patient more vulnerable to the development of tachyarrhythmias that can degenerate into a life-threatening VF episode.

2

Other forms of non-sleep related tachycardia, specifically supraventricular (SVT), are relatively benign unless episodic or prolonged. In a patient with compromised cardiac function, though, any form of tachyarrhythmia carries the potential of degrading into a life-threatening condition. Despite these increased risks, the current standard of care for treating CCD patients still relies on palliative patient management, which recognizes the risk of tachyarrhythmias occurring upon patient awakening as an unavoidable side effect of natural circadian rhythm without specific care guidelines to lessen the risk.

The standard of care for managing CCD in general continues to evolve. For instance, new therapeutic approaches that employ electrical stimulation of neural structures that directly address the underlying cardiac autonomic nervous system imbalance and dysregulation have been proposed. In one form, controlled stimulation of the cervical vagus nerve beneficially modulates cardiovascular regulatory function. Currently, vagus nerve stimulation (VNS) is only approved for the clinical treatment of drug-refractory epilepsy and depression, although VNS has been proposed as a therapeutic treatment of CHF in general and has been demonstrated in canine studies as efficacious in simulated treatment of AF and heart failure, such as described in Zhang et al., "Therapeutic Effects of Selective Atrioventricular Node Vagal Stimulation in Atrial Fibrillation and Heart Failure," *J. Cardiovasc. Electrophysiol.*, Vol. pp. 1-6 (Jul. 9, 2012), the disclosure of which is incorporated by reference.

Conventional general therapeutic alteration of cardiac vagal efferent activation through electrical stimulation targets only the efferent nerves of the parasympathetic nervous system, such as described in Sabbah et al., "Vagus Nerve Stimulation in Experimental Heart Failure," *Heart Fail. Rev.*, 16:171-178 (2011), the disclosure of which is incorporated by reference. The Sabbah paper discusses canine studies using a vagus nerve stimulation system, manufactured by BioControl Medical Ltd., Yehud, Israel, which includes an electrical pulse generator, right ventricular endocardial sensing lead, and right vagus nerve cuff stimulation lead. The sensing lead enables stimulation of the right vagus nerve in a highly specific manner, which involves closed-loop synchronization of the vagus nerve stimulation pulse to the cardiac cycle. An asymmetric tri-polar nerve cuff electrode is implanted on the right vagus nerve at the mid-cervical position. The electrode provides cathodic induction of action potentials while simultaneously applying asymmetric anodal blocks that lead to preferential activation of vagal efferent fibers. Electrical stimulation of the right cervical vagus nerve is delivered only when heart rate increases beyond a preset threshold. Stimulation is provided at an impulse rate and intensity intended to reduce basal heart rate by ten percent by preferential stimulation of efferent vagus nerve fibers leading to the heart while blocking afferent neural impulses to the brain. Although effective in partially restoring baroreflex sensitivity and, in the canine model, increasing left ventricular ejection fraction and decreasing left ventricular end diastolic and end systolic volumes, the degree of therapeutic effect on parasympathetic activation occurs through incidental recruitment of afferent parasympathetic nerve fibers in the vagus, as well as through recruitment of efferent fibers. Efferent stimulation alone is less effective at restoring autonomic balance than bi-directional stimulation.

Other uses of electrical nerve stimulation for therapeutic treatment of various cardiac and physiological conditions are described. For instance, U.S. Pat. No. 6,600,954, issued Jul. 29, 2003 to Cohen et al. discloses a method and apparatus for selective control of nerve fiber activations. An electrode

device is applied to a nerve bundle capable of generating, upon activation, unidirectional action potentials that propagate through both small diameter and large diameter sensory fibers in the nerve bundle, and away from the central nervous system. The device is particularly useful for reducing pain sensations in the legs and arms.

U.S. Pat. No. 6,684,105, issued Jan. 27, 2004 to Cohen et al. discloses an apparatus for treatment of disorders by unidirectional nerve stimulation. An apparatus for treating a specific condition includes a set of one or more electrode devices that are applied to selected sites of the central or peripheral nervous system of the patient. For some applications, a signal is applied to a nerve, such as the vagus nerve, to stimulate efferent fibers and treat motility disorders, or to a portion of the vagus nerve innervating the stomach to produce a sensation of satiety or hunger. For other applications, a signal is applied to the vagus nerve to modulate electrical activity in the brain and rouse a comatose patient, or to treat epilepsy and involuntary movement disorders.

U.S. Pat. No. 7,123,961, issued Oct. 17, 2006 to Kroll et al. discloses stimulation of autonomic nerves. An autonomic nerve is stimulated to affect cardiac function using a stimulation device in electrical communication with the heart by way of three leads suitable for delivering multi-chamber stimulation and shock therapy. For arrhythmia detection, the device utilizes atrial and ventricular sensing circuits to sense cardiac signals to determine whether a rhythm is physiologic or pathologic. The timing intervals between sensed events are classified by comparing them to a predefined rate zone limit and other characteristics to determine the type of remedial therapy needed, which includes bradycardia pacing, anti-tachycardia pacing, cardioversion shocks (synchronized with an R-wave), or defibrillation shocks (delivered asynchronously).

U.S. Pat. No. 7,225,017, issued May 29, 2007 to Shelchuk discloses terminating ventricular tachycardia in connection with any stimulation device that is configured or configurable to stimulate nerves, or stimulate and shock a patient's heart. Parasympathetic stimulation is used to augment anti-tachycardia pacing, cardioversion, or defibrillation therapy. To sense atrial or ventricular cardiac signals and provide chamber pacing therapy, particularly on the left side of the patient's heart, the stimulation device is coupled to a lead designed for placement in the coronary sinus or its tributary veins. Cardioversion stimulation is delivered to a parasympathetic pathway upon detecting a ventricular tachycardia. A stimulation pulse is delivered via the lead to one or more electrodes positioned proximate to the parasympathetic pathway according to stimulation pulse parameters based at least in part on the probability of reinitiation of an arrhythmia.

U.S. Pat. No. 7,277,761, issued Oct. 2, 2007 to Shelchuk discloses vagal stimulation for improving cardiac function in heart failure or CHF patients. An autonomic nerve is stimulated to affect cardiac function using a stimulation device in electrical communication with the heart by way of three leads suitable for delivering multi-chamber endocardial stimulation and shock therapy. Where the stimulation device is intended to operate as an implantable cardioverter-defibrillator (ICD), the device detects the occurrence of an arrhythmia, and automatically applies an appropriate therapy to the heart aimed at terminating the detected arrhythmia. Defibrillation shocks are generally of moderate to high energy level, delivered asynchronously, and pertaining exclusively to the treatment of fibrillation.

U.S. Pat. No. 7,295,881, issued Nov. 13, 2007 to Cohen et al. discloses nerve branch-specific action potential activation, inhibition and monitoring. Two preferably unidirectional

electrode configurations flank a nerve junction from which a preselected nerve branch issues, proximally and distally to the junction, with respect to the brain. Selective nerve branch stimulation can be used in conjunction with nerve-branch specific stimulation to achieve selective stimulation of a specific range of fiber diameters, substantially restricted to a preselected nerve branch, including heart rate control, where activating only the vagal B nerve fibers in the heart, and not vagal A nerve fibers that innervate other muscles, can be desirable.

U.S. Pat. No. 7,778,703, issued Aug. 17, 2010 to Gross et al. discloses selective nerve fiber stimulation for treating heart conditions. An electrode device is adapted to be coupled to a vagus nerve of a subject and a control unit drives the electrode device by applying stimulating and inhibiting currents to the vagus nerve, which are capable of respectively inducing action potentials in a therapeutic direction in a first set and a second set of nerve fibers in the vagus nerve and inhibiting action potentials in the therapeutic direction in the second set of nerve fibers only. The nerve fibers in the second set have larger diameters than the nerve fibers in the first set. Typically, the system is configured to treat heart failure or heart arrhythmia, such as atrial fibrillation or tachycardia by slowing or stabilizing the heart rate, or reducing cardiac contractility.

U.S. Pat. No. 7,813,805, issued Oct. 12, 2010 to Farazi and U.S. Pat. No. 7,869,869, issued Jan. 11, 2011 to Farazi both disclose subcardiac threshold vagus nerve stimulation. A vagus nerve stimulator is configured to generate electrical pulses below a cardiac threshold, which are transmitted to a vagus nerve, so as to inhibit or reduce injury resulting from ischemia. For arrhythmia detection, a heart stimulator utilizes atrial and ventricular sensing circuits to sense cardiac signals to determine whether a rhythm is physiologic or pathologic. In low-energy cardioversion, an ICD device typically delivers a cardioversion stimulus synchronously with a QRS complex; thus, avoiding the vulnerable period of the T-wave and avoiding an increased risk of initiation of VF. In general, if anti-tachycardia pacing or cardioversion fails to terminate a tachycardia, then, for example, after a programmed time interval or if the tachycardia accelerates, the ICD device initiates defibrillation therapy.

Finally, U.S. Pat. No. 7,885,709, issued Feb. 8, 2011 to Ben-David discloses nerve stimulation for treating disorders. A control unit drives an electrode device to stimulate the vagus nerve, so as to modify heart rate variability, or to reduce heart rate, by suppressing the adrenergic (sympathetic) system. Typically, the system is configured to treat heart failure or heart arrhythmia, such as atrial fibrillation or tachycardia. In one embodiment, a control unit is configured to drive an electrode device to stimulate the vagus nerve, so as to modify heart rate variability to treat a condition of the subject. Therapeutic effects of reduction in heart rate variability include the narrowing of the heart rate range, thereby eliminating very slow heart rates and very fast heart rates. For this therapeutic application, the control unit is typically configured to reduce low-frequency heart rate variability, and to adjust the level of stimulation applied based on the circadian and activity cycles of the subject. Therapeutic effects also include maximizing the mechanical efficiency of the heart by maintaining relatively constant ventricular filling times and pressures. For example, this therapeutic effect may be beneficial for subjects suffering from atrial fibrillation, in which fluctuations in heart filling times and pressure reduce cardiac efficiency.

Accordingly, a need remains for an approach to ameliorate tachyarrhythmic risk in a heart failure patient during awakening.

Excessive sustained activation of the sympathetic nervous system has a deleterious effect on long-term cardiac performance and increases the risk of tachyarrhythmias during awakening. In general, bi-directional afferent and efferent neural stimulation through the vagus nerve can beneficially restore autonomic balance and improve long term clinical outcome. Upon sensing a patient's awakening, VNS can be delivered therapeutically through an implantable vagus neurostimulator and electrode lead to a patient in an enhanced dose for a fixed period of time, absent arrhythmogenesis. Upon the expiration of the fixed period, other VNS doses can be engaged, such as a maintenance dose, if no tachyarrhythmia is present, and a restorative dose, which is delivered when the patient experiences a tachyarrhythmic event.

One embodiment provides an implantable neurostimulator-implemented method for managing tachyarrhythmias through vagus nerve stimulation. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers comprising the cervical vagus nerve of a patient. Operating modes are stored in the pulse generator. An enhanced dose of the electrical therapeutic current is parametrically defined and tuned to prevent initiation of or disrupt tachyarrhythmia upon the patient's awakening from a sleep state through at least one of continuously-cycling, intermittent and periodic electrical pulses. A maintenance dose of the electrical therapeutic stimulation is parametrically defined and tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses to be delivered at a lower intensity, which could be a lower output current, lower duty cycle, lower frequency, or shorter pulse width, than the enhanced dose. A restorative dose of the electrical therapeutic stimulation is parametrically defined and tuned to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity, which could be higher output current, higher duty cycle, higher frequency, or longer pulse width, than the maintenance dose. The patient's physiological state is monitored using at least one sensor, such as an accelerometer to sense the patient's posture and movements, a minute ventilation sensor to monitor the patient's respiration, and a heart rate sensor to monitor the patient's heart rate. The patient's normative physiology is monitored via a physiological sensor included in the implantable neurostimulator, and upon sensing a condition indicative of tachyarrhythmia, the intensity of the enhanced dose can be increased. The increase can be progressive based on the patient's heart rate trajectory, with the intensity increasing multiple times as the tachyarrhythmia fails to respond to the VNS stimulation or the delivery of the enhanced dose can be maximized based on the patient's heart rate trajectory. If the physiological sensors detect a condition indicative of bradyarrhythmia, the enhanced dose is suspended. Upon an expiration of the period of time for delivery of the enhanced dose, the maintenance dose can be delivered if the patient is not experiencing a tachyarrhythmic episode at the moment. If the patient is experiencing tachyarrhythmia at the time the period for delivery ends, the restorative dose can be delivered.

By improving autonomic balance and cardiovascular regulatory function, therapeutic VNS operates acutely to decrease heart rate, reflexively increase heart rate variability and coronary flow, reduce cardiac workload through vasodilation, and improve left ventricular relaxation without aggravating comorbid tachyarrhythmia or other cardiac arrhythmic con-

ditions. Over the long term, low dosage VNS provides the chronic benefits of decreased negative cytokine production, increased baroreflex sensitivity, increased respiratory gas exchange efficiency, favorable gene expression, renin-angiotensin-aldosterone system down-regulation, and anti-arrhythmic, anti-apoptotic, and ectopy-reducing anti-inflammatory effects. In short term, the delivery of the enhanced dose following the patient's awakening helps decrease the risk of having a sudden cardiac death due to a diurnal peak in VT.

Still other embodiments of the present invention will become readily apparent to those skilled in the art from the following detailed description, wherein are described embodiments by way of illustrating the best mode contemplated for carrying out the invention. As will be realized, the invention is capable of other and different embodiments and its several details are capable of modifications in various obvious respects, all without departing from the spirit and the scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a front anatomical diagram showing, by way of example, placement of an implantable vagus stimulation device in a male patient, in accordance with one embodiment.

FIGS. 2A and 2B are diagrams respectively showing the implantable neurostimulator and the simulation therapy lead of FIG. 1.

FIG. 3 is a graph showing, by way of example, the relationship between the targeted therapeutic efficacy and the extent of potential side effects resulting from use of the implantable neurostimulator of FIG. 1.

FIG. 4 is a graph showing, by way of example, the optimal duty cycle range based on the intersection depicted in FIG. 3.

FIG. 5 is a timing diagram showing, by way of example, a stimulation cycle and an inhibition cycle of VNS as provided by implantable neurostimulator of FIG. 1.

FIG. 6 is a flow diagram showing an implantable neurostimulator-implemented method for managing tachyarrhythmias upon awakening through vagus nerve stimulation, in accordance with one embodiment.

FIG. 7 is a flow diagram showing a routine for delivering an enhanced dose of VNS stimulation upon the patient's awakening for use with the method of FIG. 6, in accordance with one embodiment.

FIG. 8 is a flow diagram showing a routine for storing operating modes for use with the method of FIG. 6.

DETAILED DESCRIPTION

Changes in autonomic control of the cardiovascular systems of patients suffering from CHF and other cardiovascular diseases push the autonomic nervous system out of balance and favor increased sympathetic and decreased parasympathetic central outflow. The imbalance is accompanied by pronounced elevation of basal heart rate arising from chronic sympathetic hyperactivation along the neurocardiac axis, which is exacerbated during awakening by the surge in sympathetic activity that is a part of natural human circadian rhythms.

Peripheral neurostimulation therapies that target the imbalance of the autonomic nervous system have been shown to improve clinical outcomes in patients treated for three to twelve months. Specifically, bi-directional autonomic regulation therapy results in simultaneous creation and propaga-

tion of efferent and afferent action potentials within afferent and efferent nerve fibers comprising the vagus nerve. The therapy directly restores autonomic balance by engaging both medullary and cardiovascular reflex control components of the autonomic nervous system. Upon stimulation of the cervical vagus nerve, action potentials propagate away from the stimulation site in two directions, efferently toward the heart and afferently toward the brain. Efferent action potentials influence the intrinsic cardiac nervous system and the heart, while afferent action potentials influence central elements of the nervous system.

An implantable vagus nerve stimulator with integrated heart rate sensor, such as used to treat drug-refractory epilepsy and depression, can be adapted for use in managing chronic cardiac dysfunction during patient awakening through therapeutic bi-directional vagal stimulation. FIG. 1 is a front anatomical diagram showing, by way of example, placement of an implantable vagus nerve stimulation (VNS) device **11** in a male patient **10**, in accordance with one embodiment. The VNS provided through the stimulation device **11** operates under several mechanisms of action. These mechanisms include increasing parasympathetic outflow and inhibiting sympathetic effects by blocking norepinephrine release. More importantly, VNS triggers the release of acetylcholine (ACh) into the synaptic cleft, which has beneficial anti-arrhythmic, anti-apoptotic, and ectopy-reducing anti-inflammatory effects.

The implantable vagus stimulation device **11** includes at least three implanted components, an implantable neurostimulator **12**, a therapy lead **13**, and helical electrodes **14**. The implantable vagus stimulation device **11** can be remotely accessed following implant through an external programmer by which the neurostimulator **12** can be remotely checked and programmed by healthcare professionals; an external magnet, such as described in commonly-assigned U.S. Pat. No. 8,600,505, entitled "Implantable Device For Facilitating Control Of Electrical Stimulation Of Cervical Vagus Nerves For Treatment Of Chronic Cardiac Dysfunction," Ser. No. 13/314,130, filed on Dec. 7, 2011, the disclosure of which is incorporated by reference, for basic patient control; and an electromagnetic controller, such as described in commonly-assigned U.S. Pat. No. 8,571,654, entitled "Vagus Nerve Neurostimulator With Multiple Patient-Selectable Modes For Treating Chronic Cardiac Dysfunction," Ser. No. 13/352,244, filed on Jan. 17, 2012, the disclosure of which is incorporated by reference, that enables the patient **10** to exercise increased control over therapy delivery and suspension. Together, the implantable vagus stimulation device **11** and one or more of the external components form a VNS therapeutic delivery system.

The neurostimulator **12** is implanted in the patient's right or left pectoral region generally on the same side (ipsilateral) as the vagus nerve **15, 16** to be stimulated, although other neurostimulator-vagus nerve configurations, including contra-lateral and bi-lateral are possible. The helical electrodes **14** are generally implanted on the vagus nerve **15, 16** about halfway between the clavicle **19a-b** and the mastoid process. The therapy lead **13** and helical electrodes **14** are implanted by first exposing the carotid sheath and chosen vagus nerve **15, 16** through a latero-cervical incision on the ipsilateral side of the patient's neck **18**. The helical electrodes **14** are then placed onto the exposed nerve sheath and tethered. A subcutaneous tunnel is formed between the respective implantation sites of the neurostimulator **12** and helical electrodes **14**, through which the therapy lead **13** is guided to the neurostimulator **12** and securely connected.

In one embodiment, the stimulation device **11** delivers VNS while the patient **10** is awake. The stimulation device **11** bi-directionally stimulates the vagus nerve **15, 16** through multimodal application of continuously-cycling, intermittent and periodic electrical stimuli, which are parametrically defined through stored stimulation parameters and timing cycles. Upon patient awakening, an enhanced dose of VNS is delivered to counter the increased tachyarrhythmic risk caused by the natural circadian rhythm-triggered surge of sympathetic activity and increased heart rate. In a further embodiment, tachyarrhythmias outside of awakening can be managed through application of a restorative dose of VNS upon the sensing of a condition indicative of tachyarrhythmias, such as described in commonly-assigned U.S. patent application, entitled "Implantable Neurostimulator-Implemented Method for Managing Tachyarrhythmias through Vagus Nerve Stimulation," Ser. No. 13/673,766, filed on Nov. 9, 2012, published as US 2014/0135862 A1, pending, the disclosure of which is incorporated by reference. In a still further embodiment, bradycardia in VNS-titrated patients can be managed through suspension of on-going low-level VNS, such as described in commonly-assigned U.S. Pat. No. 8,688,212, entitled "Implantable Neurostimulator-Implemented Method for Managing Bradycardia through Vagus Nerve Stimulation," Ser. No. 13/554,656, filed on Jul. 20, 2012, the disclosure of which is incorporated by reference.

Both sympathetic and parasympathetic nerve fibers are stimulated. Cervical vagus nerve stimulation results in propagation of action potentials from the site of stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers comprising the cervical vagus nerve to restore cardiac autonomic balance. Afferent action potentials propagate toward the parasympathetic nervous system's origin in the medulla in the nucleus ambiguus, nucleus tractus solitarius, and the dorsal motor nucleus, as well as towards the sympathetic nervous system's origin in the intermediolateral cell column of the spinal cord. Efferent action potentials propagate toward the heart **17** to activate the components of the heart's intrinsic nervous system. Either the left or right vagus nerve **15, 16** can be stimulated by the stimulation device **11**. The right vagus nerve **16** has a moderately lower stimulation threshold than the left vagus nerve **15** for heart rate effects at the same parametric levels.

The VNS therapy is delivered autonomously to the patient's vagus nerve **15, 16** through three implanted components that include a neurostimulator **12**, therapy lead **13**, and helical electrodes **14**. FIGS. 2A and 2B are diagrams respectively showing the implantable neurostimulator **12** and the stimulation therapy lead **13** of FIG. 1. In one embodiment, the neurostimulator **12** can be adapted from a VNS Therapy AspireSR Model 106 pulse generator, manufactured and sold by Cyberonics, Inc., Houston, Tex., although other manufactures and types of single-pin receptacle implantable VNS neurostimulators with integrated leadless heart rate sensors could also be used. The stimulation therapy lead **13** and helical electrodes **14** are generally fabricated as a combined assembly and can be adapted from a Model 302 lead, PerenniaDURA Model 303 lead, or PerenniaFLEX Model 304 lead, also manufactured and sold by Cyberonics, Inc., in two sizes based on helical electrode inner diameter, although other manufactures and types of single-pin receptacle-compatible therapy leads and electrodes could also be used.

Referring first to FIG. 2A, the neurostimulator **12** provides multimodal vagal stimulation. In a maintenance mode, the neurostimulator **12** is parametrically programmed to deliver continuously-cycling, intermittent and periodic ON-OFF

cycles of VNS are delivered that produce action potentials in the underlying nerves that propagate bi-directionally. In a restorative mode, the neurostimulator **12** is parametrically programmed to deliver VNS tuned to prevent initiation of or disrupt tachyarrhythmia through continuously-cycling, intermittent and periodic ON-OFF cycles of VNS delivered at higher intensity, which could be higher output current, higher duty cycle, higher frequency, longer pulse width, or a combination of the foregoing parameters, than the maintenance dose are delivered in response to the onset or progression of tachyarrhythmias. In an enhanced mode, which is further described with reference to FIGS. **6** and **7**, the neurostimulator **12** is parametrically programmed to deliver the VNS tuned to prevent initiation of or disrupt tachyarrhythmia specifically upon patient awakening through continuously-cycling, intermittent and periodic ON-OFF cycles of VNS is delivered at delivered at a higher intensity than the maintenance mode, higher output current, higher duty cycle, higher frequency, longer pulse width, or a combination of the foregoing parameters.

The neurostimulator **12** includes an electrical pulse generator that is tuned to restore autonomic balance by triggering action potentials that propagate both afferently and efferently within the vagus nerve **15**, **16**. The neurostimulator **12** is enclosed in a hermetically sealed housing **21** constructed of a biocompatible, implantation-safe material, such as titanium. The housing **21** contains electronic circuitry **22** powered by a primary battery **23**, such as a lithium carbon monofluoride battery. The electronic circuitry **22** is implemented using complementary metal oxide semiconductor integrated circuits that include a microprocessor controller that executes a control program according to stored stimulation parameters and timing cycles; a voltage regulator that regulates system power; logic and control circuitry, including a recordable memory **29** within which the stimulation parameters are stored, that controls overall pulse generator function, receives and implements programming commands from the external programmer, or other external source, collects and stores telemetry information, processes sensory input, and controls scheduled and sensory-based therapy outputs; a transceiver that remotely communicates with the external programmer using radio frequency signals; an antenna, which receives programming instructions and transmits the telemetry information to the external programmer; and a reed switch **30** that provides remote access to the operation of the neurostimulator **12** using an external programmer, a simple patient magnet, or an electromagnetic controller. The recordable memory **29** can include both volatile (dynamic) and persistent (static) forms of memory, such as firmware within which the stimulation parameters and timing cycles can be stored. Other electronic circuitry and components are possible.

Externally, the neurostimulator **12** includes a header **24** to securely receive and connect to the therapy lead **13**. In one embodiment, the header **24** encloses a receptacle **25** into which a single pin for the therapy lead **13** can be received, although two or more receptacles could also be provided, along with the requisite additional electronic circuitry **22**. The header **24** internally includes a lead connector block (not shown) and a set of set screws **26**.

The housing **21** can also contain a heart rate sensor **31** that is electrically interfaced with the logic and control circuitry, which receives the patient's sensed heart rate as sensory inputs. The heart rate sensor **31** monitors heart rate using an ECG-type electrode. Through the electrode, the patient's heart beat can be sensed by detecting ventricular depolarization. In a further embodiment, a plurality of electrodes can be used to sense voltage differentials between electrode pairs,

which can undergo signal processing for cardiac physiological measures, for instance, detection of the P-wave, QRS complex, and T-wave. The heart rate sensor **31** provides the sensed heart rate to the control and logic circuitry as sensory inputs that can be used to monitor whether the patient **10** is awake or asleep, as further described infra with reference to FIG. **6** and determine the presence of possible tachyarrhythmias, particularly VT.

In a further embodiment, the housing **21** contains a minute ventilation sensor **32** that is electrically interfaced with the logic and control circuitry, which receives the patient's respiratory dynamics as sensory inputs. The minute ventilation sensor **32**, such as described in U.S. Pat. No. 7,092,757, issued Aug. 15, 2006, to Larson et al., the disclosure of which is incorporated by reference, measures the patient's respiratory rate and tidal volume, and calculates the patient's minute ventilation volume. The minute ventilation sensor **32** provides the minute ventilation volume to the control and logic circuitry as sensory inputs that can be used to determine whether the patient is awake.

In a still further embodiment, the housing **21** contains an accelerometer **33** that is electrically interfaced with the logic and control circuitry, which receives the patient's physical movement as sensory inputs. The minute ventilation sensor **32** may be combined into a blended sensor with at least one accelerometer **33**. The accelerometer **33** contains the circuitry and mechanical components necessary to measure acceleration of the patient's body along at least two axes, and may include multiple uniaxial accelerometers, a dual axial accelerometer, or a triaxial accelerometer. By measuring the acceleration along multiple axes, the accelerometer **33** provides sensory inputs that can be used to determine the patient's posture and rate of movement and whether the patient has fallen or awakened from sleep. In a further embodiment, the accelerometer **33** can be located separately from the minute ventilation sensor **32**, either on the interior or exterior of the housing **21**.

The neurostimulator **12** is preferably interrogated prior to implantation and throughout the therapeutic period with a healthcare provider-operable external programmer and programming wand (not shown) for checking proper operation, downloading recorded data, diagnosing problems, and programming operational parameters, such as described in commonly-assigned U.S. Pat. Nos. 8,60,505 and 8,571,654, cited supra. Generally, use of the external programmer is restricted to healthcare providers, while more limited manual control is provided to the patient through "magnet mode." In one embodiment, the external programmer executes application software specifically designed to interrogate the neurostimulator **12**. The programming computer interfaces to the programming wand through a standardized wired or wireless data connection. The programming wand can be adapted from a Model 201 Programming Wand, manufactured and sold by Cyberonics, Inc. and the application software can be adapted from the Model 250 Programming Software suite, licensed by Cyberonics, Inc. Other configurations and combinations of external programmer, programming wand and application software are possible.

The neurostimulator **12** delivers VNS under control of the electronic circuitry **22**. The stored stimulation parameters are programmable. Each stimulation parameter can be independently programmed to define the characteristics of the cycles of therapeutic stimulation and inhibition to ensure optimal stimulation for a patient **10**. The programmable stimulation parameters include output current, signal frequency, pulse width, signal ON time, signal OFF time, magnet activation (for VNS specifically triggered by "magnet mode"), and reset

parameters. Other programmable parameters are possible. In addition, sets or “profiles” of preselected stimulation parameters can be provided to physicians with the external programmer and fine-tuned to a patient’s physiological requirements prior to being programmed into the neurostimulator **12**, such as described in commonly-assigned U.S. Pat. No. 8,630,709, entitled “Computer-Implemented System and Method for Selecting Therapy Profiles of Electrical Stimulation of Cervical Vagus Nerves for Treatment of Chronic Cardiac Dysfunction,” Ser. No. 13/314,138, filed on Dec. 7, 2011, the disclosure of which is incorporated by reference.

Referring next to FIG. 2B, the therapy lead **13** delivers an electrical signal from the neurostimulator **12** to the vagus nerve **15**, **16** via the helical electrodes **14**. On a proximal end, the therapy lead **13** has a lead connector **27** that transitions an insulated electrical lead body to a metal connector pin **28**. During implantation, the connector pin **28** is guided through the receptacle **25** into the header **24** and securely fastened in place using the set screws **26** to electrically couple the therapy lead **13** to the neurostimulator **12**. On a distal end, the therapy lead **13** terminates with the helical electrode **14**, which bifurcates into a pair of anodic and cathodic electrodes **62** (as further described infra with reference to FIG. 4). In one embodiment, the lead connector **27** is manufactured using silicone and the connector pin **28** is made of stainless steel, although other suitable materials could be used, as well. The insulated lead body **13** utilizes a silicone-insulated alloy conductor material.

Preferably, the helical electrodes **14** are placed over the cervical vagus nerve **15**, **16** at the location below where the superior and inferior cardiac branches separate from the cervical vagus nerve. In alternative embodiments, the helical electrodes may be placed at a location above where one or both of the superior and inferior cardiac branches separate from the cervical vagus nerve. In one embodiment, the helical electrodes **14** are positioned around the patient’s vagus nerve oriented with the end of the helical electrodes **14** facing the patient’s head. In an alternate embodiment, the helical electrodes **14** are positioned around the patient’s vagus nerve **15**, **16** oriented with the end of the helical electrodes **14** facing the patient’s heart **17**. At the distal end, the insulated electrical lead body **13** is bifurcated into a pair of lead bodies that are connected to a pair of electrodes proper. The polarity of the electrodes could be configured into a monopolar cathode, a proximal anode and a distal cathode, or a proximal cathode and a distal anode.

Therapeutically, the VNS is delivered as a multimodal set of therapeutic and event-based doses, which are system output behaviors that are pre-specified within the neurostimulator **12** through the stored stimulation parameters and timing cycles implemented in firmware and executed by the microprocessor controller. The therapeutic doses include a cardiac cycle-independent maintenance dose that includes continuously-cycling, intermittent and periodic cycles of electrical stimulation during periods in which the pulse amplitude is greater than 0 mA (“therapy ON”) and during periods in which the pulse amplitude is 0 mA (“therapy OFF”). The therapeutic doses also include a restorative dose at a higher level of intensity than the maintenance dose, which could be higher output current, higher duty cycle, higher frequency, longer pulse width, or a combination of the foregoing parameters, in response to the presence of tachyarrhythmias. Finally, the therapeutic doses also include an enhanced dose of VNS tuned to prevent initiation of or disrupt tachyarrhythmia upon awakening through continuously-cycling, intermittent and periodic ON-OFF cycles of VNS delivered at a higher intensity than the maintenance dose, which could be higher

output current, higher duty cycle, higher frequency, longer pulse width, or a combination of the foregoing parameters, in response to the presence of tachyarrhythmias upon the patient’s **10** awakening.

The neurostimulator **12** can operate either with or without an integrated heart rate sensor (provided that patient physiology can be monitored through some other type of sensing mechanism), such as respectively described in commonly-assigned U.S. Pat. No. 8,577,458, entitled “Implantable Device for Providing Electrical Stimulation of Cervical Vagus Nerves for Treatment of Chronic Cardiac Dysfunction with Leadless Heart Rate Monitoring,” Ser. No. 13/314,126, filed on Dec. 7, 2011, and U.S. patent application, entitled “Implantable Device for Providing Electrical Stimulation of Cervical Vagus Nerves for Treatment of Chronic Cardiac Dysfunction,” Ser. No. 13/314,119, filed on Dec. 7, 2011, pending, the disclosures of which are hereby incorporated by reference herein in their entirety. Additionally, where an integrated leadless heart rate monitor is available, the neurostimulator **12** can provide autonomic cardiovascular drive evaluation and self-controlled titration, such as respectively described in commonly-assigned U.S. patent application, entitled “Implantable Device for Evaluating Autonomic Cardiovascular Drive in a Patient Suffering from Chronic Cardiac Dysfunction,” Ser. No. 13/314,133, filed on Dec. 7, 2011, published as US 2013/0158616 A1, pending, and U.S. patent application, entitled “Implantable Device for Providing Electrical Stimulation of Cervical Vagus Nerves for Treatment of Chronic Cardiac Dysfunction with Bounded Titration,” Ser. No. 13/314,135, filed on Dec. 7, 2011, published as US 2013/0158617 A1, pending, the disclosures of which are incorporated by reference. Finally, the neurostimulator **12** can be used to ameliorate heart rate increase and decrease tachyarrhythmic risk following exercise, such as described in commonly-assigned U.S. patent application, entitled “Implantable Neurostimulator-Implemented Method for Enhancing Heart Failure Patient Awakening Through Vagus Nerve Stimulation,” Ser. No. 13/673,811, filed on Nov. 9, 2012, published as US 2014/0135864 A1, pending, the disclosure of which is incorporated by reference.

Therapeutically, VNS is delivered during the period following awakening independent of cardiac cycle and in an enhanced dose having an intensity that is insufficient to elicit side-effects, such as cardiac arrhythmias. The selection of duty cycle is a tradeoff among competing medical considerations. FIG. 3 is a graph **40** showing, by way of example, the relationship between the targeted therapeutic efficacy **43** and the extent of potential side effects **44** resulting from use of the implantable neurostimulator **12** of FIG. 1. The x-axis represents the duty cycle **41**. The duty cycle is determined by dividing the stimulation ON time by the sum of the ON and OFF times of the neurostimulator **12** during a single ON-OFF cycle. However, the stimulation time may also need to include ramp-up time and ramp-down time, where the stimulation frequency exceeds a minimum threshold (as further described infra with reference to FIG. 5). The y-axis represents physiological response **42** to VNS therapy. The physiological response **42** can be expressed quantitatively for a given duty cycle **41** as a function of the targeted therapeutic efficacy **43** and the extent of potential side effects **44**, as described infra. The maximum level of physiological response **42** (“max”) signifies the highest point of targeted therapeutic efficacy **43** or potential side effects **44**.

Targeted therapeutic efficacy **43** and the extent of potential side effects **44** can be expressed as functions of duty cycle **41** and physiological response **42**. The targeted therapeutic efficacy **43** represents the intended effectiveness of VNS in pro-

voicing a beneficial physiological response for a given duty cycle and can be quantified by assigning values to the various acute and chronic factors that contribute to the physiological response **42** of the patient **10** due to the delivery of therapeutic VNS. Acute factors that contribute to the targeted therapeutic efficacy **43** include beneficial changes in heart rate variability and increased coronary flow, reduction in cardiac workload through vasodilation, and improvement in left ventricular relaxation. Chronic factors that contribute to the targeted therapeutic efficacy **43** include improved cardiovascular regulatory function, as well as decreased negative cytokine production, increased baroreflex sensitivity, increased respiratory gas exchange efficiency, favorable gene expression, renin-angiotensin-aldosterone system down-regulation, anti-arrhythmic, anti-apoptotic, and ectopy-reducing anti-inflammatory effects. These contributing factors can be combined in any manner to express the relative level of targeted therapeutic efficacy **43**, including weighting particular effects more heavily than others or applying statistical or numeric functions based directly on or derived from observed physiological changes. Empirically, targeted therapeutic efficacy **43** steeply increases beginning at around a 5% duty cycle, and levels off in a plateau near the maximum level of physiological response at around a 30% duty cycle. Thereafter, targeted therapeutic efficacy **43** begins decreasing at around a 50% duty cycle and continues in a plateau near a 25% physiological response through the maximum 100% duty cycle.

The intersection **45** of the targeted therapeutic efficacy **43** and the extent of potential side effects **44** represents one optimal duty cycle range for VNS. FIG. 4 is a graph **50** showing, by way of example, the optimal duty cycle range **53** based on the intersection **45** depicted in FIG. 3. The x-axis represents the duty cycle **51** as a percentage of stimulation time over inhibition time. The y-axis represents therapeutic points **52** reached in operating the neurostimulator **12** at a given duty cycle **51**. The optimal duty range **53** is a function **54** of the intersection **44** of the targeted therapeutic efficacy **43** and the extent of potential side effects **44**. The therapeutic operating points **52** can be expressed quantitatively for a given duty cycle **51** as a function of the values of the targeted therapeutic efficacy **43** and the extent of potential side effects **44** at their point of intersection in the graph **40** of FIG. 3. The optimal therapeutic operating point **55** ("max") signifies a tradeoff that occurs at the point of highest targeted therapeutic efficacy **43** in light of lowest potential side effects **44** and that point will typically be found within the range of a 5% to 30% duty cycle **51**. Other expressions of duty cycles and related factors are possible.

Therapeutically and in the absence of patient physiology of possible medical concern, such as cardiac arrhythmias, or following the patient's awakening from sleep, VNS is delivered in a low level maintenance dose that uses alternating cycles of stimuli application (ON) and stimuli inhibition (OFF) that are tuned to activate both afferent and efferent pathways. Stimulation results in parasympathetic activation and sympathetic inhibition, both through centrally-mediated pathways and through efferent activation of preganglionic neurons and local circuit neurons. FIG. 5 is a timing diagram showing, by way of example, a stimulation cycle and an inhibition cycle of VNS **60** as provided by implantable neurostimulator **12** of FIG. 1. The stimulation parameters enable the electrical stimulation pulse output by the neurostimulator **12** to be varied by both amplitude (output current **66**) and duration (pulse width **64**). The number of output pulses delivered per second determines the signal frequency **63**. In one embodiment, a pulse width in the range of 100 to 250 μ sec

delivers between 0.02 and 50 mA of output current at a signal frequency of about 20 Hz, although other therapeutic values could be used as appropriate.

In the simplest case, the stimulation time is the time period during which the neurostimulator **12** is ON and delivering pulses of stimulation. The OFF time **65** is always the time period occurring in-between stimulation times **61** during which the neurostimulator **12** is OFF and inhibited from delivering stimulation. In one embodiment, the neurostimulator **12** implements a ramp-up time **67** and a ramp-down time **68** that respectively precede and follow the ON time **62** during which the neurostimulator **12** is ON and delivering pulses of stimulation at the full output current **66**. The ramp-up time **67** and ramp-down time **68** are used when the stimulation frequency is at least 10 Hz, although other minimum thresholds could be used, and both ramp-up and ramp-down times **67**, **68** last two seconds, although other time periods could also be used. The ramp-up time **67** and ramp-down time **68** allow the strength of the output current **66** of each output pulse to be gradually increased and decreased, thereby avoiding deleterious reflex behavior due to sudden delivery or inhibition of stimulation at a programmed intensity.

The triggering of CHF compensatory mechanisms underlying a CCD increases the risk of tachyarrhythmias. In the hours following awakening, the risk of tachyarrhythmia is even higher. Although delivered in an enhanced dose upon patient awakening and, in a further embodiment, in a maintenance dose while the patient is awake, with an intensity that is insufficient to elicit side-effects, such as cardiac arrhythmias, therapeutic VNS can nevertheless potentially prevent formation of pathological tachyarrhythmias or at least ameliorate their occurrence during awakening in some patients. Although VNS has been shown to decrease defibrillation threshold, VNS is unlikely to terminate VF in the absence of defibrillation. VNS prolongs ventricular action potential duration, so may be effective in terminating VT. In addition, the effect of VNS on the AV node may be beneficial in patients with AF by slowing conduction to the ventricles and controlling ventricular rate.

While therapeutic VNS maintenance dose delivery can be suspended upon the occurrence of tachyarrhythmia and replaced with the delivery of a higher intensity VNS restorative dose that is tuned to prevent initiation of or disrupt tachyarrhythmia, neither of the doses are appropriate for the increased period of risk that a patient experiences upon waking up. The maintenance dose may be too low to prevent the occurrence of tachyarrhythmia during the diurnal peak, while the restorative dose may subject the patient to a high dose of VNS needlessly on occasions that a tachyarrhythmic event does not occur. FIG. 6 is a flow diagram showing an implantable neurostimulator-implemented method for managing tachyarrhythmias upon the patient's **10** awakening through vagus nerve stimulation **70**, in accordance with one embodiment. The method **70** is implemented on the stimulation device **11**, the operation of which is parametrically defined through stored stimulation parameters and timing cycles. The method **70** can be used for treatment of both CHF and non-CHF patients suffering from other forms of chronic cardiac dysfunction.

Preliminarily, an implantable neurostimulator **12** with an integrated heart rate sensor **31**, which includes a pulse generator **11**, a nerve stimulation therapy lead **13**, and a pair of helical electrodes **14**, is provided (step **71**). In an alternative embodiment, electrodes may be implanted with no implanted neurostimulator or leads. Power may be provided to the electrodes from an external power source and neurostimulator through wireless RF or inductive coupling. Such an embodi-

ment may result in less surgical time and trauma to the patient. In a further embodiment, the integrated heart rate sensor **31** could be omitted in lieu of other types of sensing mechanisms for measuring the patient's physiology.

The pulse generator stores a set of one or more operating modes (step **72**) that parametrically defines a low level maintenance dose, an enhanced dose, and a restorative dose of VNS stimulation, the latter two of which are higher in intensity than the maintenance dose, as further described infra with reference to FIG. **8**. A sleeping patient's **10** physiological state is regularly monitored to determine whether the patient **10** has awakened from sleep (step **73**). In a further embodiment, the risk of cardiac arrhythmias during or attendant to sleep, particularly sleep apneic episodes, can be managed by the implantable neurostimulator **12**, such as described in commonly-assigned U.S. patent application, entitled "Implantable Neurostimulator-Implemented Method For Managing Tachyarrhythmic Risk During Sleep Through Vagus Nerve Stimulation," Ser. No. 13/828,486, filed Mar. 14, 2013, published as US 2014/0277232 A1, pending, the disclosure of which is incorporated by reference. In one embodiment, heart rate is used to check the patient's physiology using the heart rate sensor **31**. A normative heart rate during sleep is generally considered to fall between 60 to 70 beats per minute (bpm). Upon awakening, the heart rate naturally rises to an awake range generally somewhere under 100 bpm, depending upon patient condition. The normative heart rate of the patient **10** is monitored and recorded periodically while asleep to determine whether the patient **10** is awakening.

In general, awakening is characterized by the gradual onset of an increased heart rate, which can be sensed by the neurostimulator **12**, as well as by evaluation of rhythm stability or related rate and rhythm morphological indicators, such as conventionally used in cardiac rhythm management devices. If the heart rate of the patient **10** is gradually elevated above the mean normative heart rate level recorded during sleep, for instance, a heart rate that gradually increases over a seven-minute period and is then maintained for a non-transitory period of time, the patient **10** is considered to be awakening. In contrast, abrupt onset of increased heart rate could be indicative of a non-sinus tachyarrhythmia.

In a still further embodiment, a minute ventilation sensor **32** can be used to determine patient awakening. Minute ventilation is closely tied to heart rate during sleep, as ventilatory volume (tidal volume) and breathing frequency (respiratory rate) decrease synchronously, as does heart rate, as the patient falls asleep, then settles into a regular pattern. Tidal volume at rest is measured by the minute ventilation sensor **32**. In general, tidal volume at rest is around 0.5 L/min and can increase up to 3 L/min at a higher intensity level of exertion. Similarly, respiratory rate at rest is measured by the minute ventilation sensor **32**. In general, respiratory rate at rest is around 12 to 16 breathes/min and can increase 40 to 50 breathes/min during maximum levels of activity. A normative activity level while asleep is established by determining means of the tidal volume and respiratory rate. If tidal volume and respiratory rate of the patient **10** respectively exceed the mean resting values of tidal volume and respiratory rate, the patient **10** is considered to be awakening. In a still further embodiment, the heart rate sensor **31** and the accelerometer **32** can be used in combination with the minute ventilation sensor **32**. Still other measures and indications of awakening are possible.

In a still further embodiment, the neurostimulator **12** can use a multiple forms of sensory data in determining whether the patient **10** has awakened. As well, the neurostimulator **12** can assign more weight to one type of sensory data over other

types of sensory data. For example, more weight can be assigned to accelerometer **33** data, which would discount a rise in heart rate that occurs while the patient **10** remains recumbent and otherwise still. Other ways of preferentially weighting the data are possible.

If the physiological state indicates that the patient **10** has not awakened from sleep (step **74**), the patient's state is checked again periodically. If the monitored physiological state is indicative of the patient **10** having awakened (step **74**), therapeutic VNS, as parametrically defined by the enhanced dose operating mode, is delivered to at least one of the vagus nerves through continuously-cycling, intermittent and periodic electrical pulses to tuned to prevent initiation of or disrupt tachyarrhythmia upon the patient's awakening (step **75**), as further described infra with reference to FIG. **7**.

Following a completion of the enhanced dose delivery (step **75**), a set of optional follow-up stimulation doses can be delivered as follows. The patient's normative physiology is monitored (step **76**). If a condition indicative of tachyarrhythmia is present (step **77**), a restorative dose of VNS stimulation is initiated (step **78**), such as further described in the commonly-assigned U.S. patent application, entitled "Implantable Neurostimulator-Implemented Method for Managing Tachyarrhythmia Through Vagus Nerve Stimulation," Ser. No. 13/673,766, filed Nov. 9, 2012, published as US 2014/0135862 A1, pending, the disclosure of which is incorporated by reference. Contrarily, in the absence of tachyarrhythmia, the presence of bradyarrhythmia is assessed (step **79**). If a condition indicative of bradyarrhythmia is detected (step **79**), the method **70** is terminated and the bradyarrhythmia is addressed, such as described in commonly-assigned U.S. Pat. No. 8,688,212, entitled "Implantable Neurostimulator-Implemented Method for Managing Bradycardia through Vagus Nerve Stimulation," Ser. No. 13/554,656, filed on Jul. 20, 2012, the disclosure of which is incorporated by reference. If a condition indicative of a bradyarrhythmia is absent (step **79**), a maintenance dose of VNS stimulation is initiated (step **80**), such as further described in the commonly-assigned U.S. patent application, entitled "Implantable Neurostimulator-Implemented Method for Managing Tachyarrhythmia Through Vagus Nerve Stimulation," Ser. No. 13/673,766, filed Nov. 9, 2012, published as US 2014/0135862 A1, pending, the disclosure of which is incorporated by reference.

The enhanced dose of VNS stimulation helps ameliorate tachyarrhythmia vulnerability during awakening. FIG. **7** is a flow diagram showing the routine **90** for providing an enhanced dose that is engaged upon the patient's **10** awakening for use in the method **70** of FIG. **6**. An enhanced dose, which has a higher intensity than the maintenance dose, is therapeutically delivered (step **91**). In one embodiment, the enhanced dose is parametrically defined with a pulse width in the range of 250 to 500 μ sec, delivering between 1.0 and 1.5 mA of output current at a signal frequency in the range of 10 to 20 Hz. The duty cycle may change significantly from nominally 10% to temporarily 50% or 100%, although other therapeutic values could be used as appropriate.

The patient's **10** normative physiology is monitored during delivery of the enhanced dose (step **92**). The enhanced dose ameliorates, but does not fully eliminate, the risk of tachyarrhythmias. In general, the onset or presence of pathological tachyarrhythmia can be determined by heart rate or rhythm, as well as rhythm stability, onset characteristics, and similar rate and rhythm morphological indicators, as conventionally detected in cardiac rhythm management devices, such as described in K. Ellenbogen et al., "Clinical Cardiac Pacing and Defibrillation," Ch. 3, pp. 68-126 (2d ed. 2000), the disclosure of which is incorporated by reference. If a

condition indicative of tachyarrhythmia is detected (step 93), the intensity of the enhanced dose is progressively increased (step 94) and delivered (step 95). The neurostimulator 12 checks whether the time period for the delivery of the enhanced dose has expired (step 96), terminating the routine 90 upon the period's expiration. In one embodiment, a fixed period of one to three hours is used, although the time period can be adjusted by a physician. In a further embodiment, the time period can be extended if a tachyarrhythmic condition occurs.

If the time period has not expired (step 96), the responsiveness of the tachyarrhythmia to the enhanced dose is assessed (step 97). Non-responsiveness to the delivery of VNS stimulation can occur during continuing heart rate elevation, which can present as no appreciable change in heart rate, insufficient heart rate decrease, or non-transitory increase in heart rate. Depending on the patient's 10 heart response trajectory, the intensity of the enhanced dose can be progressively increased by the same or similar amount each cycle (step 94-97), or, for life-threatening or paroxysmal arrhythmias, immediately increased to a strongly enhanced dose of significantly higher intensity (step 94), due to the lack of time to ramp up the intensity progressively. The amount by which the intensity of the enhanced dose is progressively increased can also depend on the heart rate trajectory. In one embodiment, the strongly enhanced dose delivery (step 94) maximizes the VNS stimulation, delivering the maximum intensity of stimulation that the neurostimulator 12 can produce.

If the tachyarrhythmia is responding to the enhanced dose delivery (step 97), therapeutic delivery of the enhanced dose at default intensity is resumed (step 91) upon the termination of the tachyarrhythmia. In a further embodiment, the intensity of the enhanced dose can be increased continuously, independently of the heart response trajectory, for the duration of the period of time.

On the other hand, as the delivery of the enhanced dose is both preventative and precautionary, heart rate could decrease in response to the enhanced dose delivery as an unintended side-effect. If a condition indicative of bradyarrhythmia is detected (step 98), the enhanced dose delivery is suspended (step 99), terminating the routine 90.

Finally, in the absence of tachyarrhythmia (step 93) or bradyarrhythmia (step 98), the neurostimulator 12 checks whether the time period for delivery of the enhanced dose has expired (step 100), terminating the routine 90 if the period has expired. Otherwise, enhanced dose delivery continues (step 91).

In a still further embodiment, delivery of the enhanced, as well as the restorative dose, can be manually triggered, increased, decreased, or suspended by providing the neurostimulator 12 with a magnetically-actuated reed switch, such as described in commonly-assigned U.S. Pat. Nos. 8,600,505 and 8,571,654, cited supra. In addition, the delivery of the enhanced dose and the maintenance dose can also be manually swapped. For instance, the switch can be used when the maintenance dose is tolerable to the patient 10, while the enhanced dose and the restorative dose are intolerable. Other uses of the switch are possible.

The recordable memory 29 in the electronic circuitry 22 of the neurostimulator 12 (shown in FIG. 2A) stores the stimulation parameters that control the overall functionality of the pulse generator 11 in providing VNS therapy. FIG. 8 is a flow diagram showing a routine 110 for storing operating modes for use with the method 70 of FIG. 6. Three operating modes are stored, which include a maintenance dose of VNS tuned to restore cardiac autonomic balance (step 111) through continuously-cycling, intermittent and periodic electrical pulses;

an enhanced dose of VNS tuned to prevent initiation of or disrupt tachyarrhythmia upon awakening through continuously-cycling, intermittent and periodic ON-OFF cycles of VNS delivered at a higher intensity than the maintenance dose (step 112); and a restorative dose tuned to prevent initiation of or disrupt tachyarrhythmia (step 113) through periodic electrical pulses delivered at a higher intensity than the maintenance dose.

In one embodiment, the autonomic regulation therapy is provided in a low level maintenance dose independent of cardiac cycle to activate both parasympathetic afferent and efferent neuronal fibers in the vagus nerve simultaneously and a high level enhanced dose. In the maintenance dose, a pulse width in the range of 250 to 500 μ sec delivering between 0.02 and 1.0 mA of output current at a signal frequency in the range of 10 to 20 Hz, and a duty cycle of 5 to 30%, although other therapeutic values could be used as appropriate.

Different enhanced doses can be provided to respond to different tachyarrhythmic events. The enhanced dose settings are physician-programmable. For a default enhanced dose, the stimulation parameters would be in the same range as the maintenance dose, but would be moderately higher, with a pulse width again in the range of 250 to 500 μ sec delivering between 1.5 and 2.0 mA of output current at a signal frequency in the range of 10 to 20 Hz. The duty cycle may change significantly from nominally 10% to temporarily 50% or 100%, although other therapeutic values could be used as appropriate. For non-life-threatening or non-paroxysmal tachyarrhythmias, the intensity of the enhanced dose is progressively increased over time by increasing output current, duty cycle, or frequency, lengthening pulse width, or through a combination of the foregoing parameters. Discretely-defined enhanced doses, each using different parameters sets, may be delivered in the course of treating a single continuing tachyarrhythmic event, such as for life-threatening or paroxysmal arrhythmias that rapidly generate and require a significantly strongly enhanced dose with no ramp up time.

In a further embodiment, the suspension and resumption of the enhanced dose, maintenance dose, or restorative dose can be titrated to gradually withdraw or introduce their respective forms of VNS.

While the invention has been particularly shown and described as referenced to the embodiments thereof, those skilled in the art will understand that the foregoing and other change in form and detail may be made therein without departing from the spirit and scope.

What is claimed is:

1. A vagus nerve neurostimulator for modulating autonomic cardiovascular drive, comprising:
 - a pulse generator, wherein the pulse generator generates a pulsed electrical signal comprising:
 - a signal ON time;
 - a signal OFF time;
 - an output current;
 - a signal frequency;
 - a pulse width; and
 - a duty cycle defined by dividing the signal ON time by the sum of the signal ON time and signal OFF time;
 - a therapy lead;
 - an electrode communicatively coupled to the pulse generator via the therapy lead, wherein the pulse generator applies the electrical signal to the electrode adapted for a vagus nerve to propagate action potentials in both afferent and efferent directions along the vagus nerve at an intensity that avoids acute physiological side effects; and

a sleep monitor, wherein the sleep monitor upon sensing a change in sleep state indicative of awakening causes the pulse generator to increase an intensity of the electrical signal to deliver an enhanced pulsed electrical signal via the therapy lead and the electrode.

2. The vagus nerve neurostimulator according to claim 1, wherein the enhanced pulsed electrical signal frequency is approximately 10 Hz.

3. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor monitors a patient's physiological state.

4. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor further comprises a heart rate sensor.

5. The vagus nerve neurostimulator according to claim 4, wherein the heart rate sensor:

- establishes a normative heart rate of a patient as a mean heart rate sensed during the sleep state;
- periodically sensing the patient's heart rate with the heart rate sensor; and
- confirming that the patient is awakening when the patient's heart rate gradually rises and is sustained at an elevated heart rate above the normative heart rate by a threshold amount.

6. The vagus nerve neurostimulator according to claim 5, wherein the heart rate monitor monitors the patient's normative physiology during the delivery of the enhanced pulsed electrical signal, and upon sensing a condition indicative of an onset of tachyarrhythmia, the vagus nerve neurostimulator delivers a second enhanced pulsed electrical signal.

7. The vagus nerve neurostimulator according to claim 6, wherein the heart rate monitor monitors the patient's normative physiology during the delivery of the enhanced pulsed electrical signal, and upon sensing a condition indicative of an onset of tachyarrhythmia, intensifying the electrical therapeutic stimulation to deliver the second enhanced pulsed electrical signal.

8. The vagus nerve neurostimulator according to claim 6, wherein second enhanced pulsed electrical signal is different than the enhanced electrical signal.

9. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor further comprises an accelerometer.

10. The vagus nerve neurostimulator according to claim 9, wherein the sleep monitor:

- establishes a normative activity level of the patient with the accelerometer as a mean frequency of movement sensed during the sleep state;
- periodically sensing the patient's activity level with the accelerometer; and
- confirming that the patient is awakening from the sleep state when the patient's activity level gradually rises and is sustained at an elevated activity level above the nor-

- mative activity level accompanied by an increased frequency of movement by a threshold amount.

11. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor further comprises a minute ventilation sensor.

12. The vagus nerve neurostimulator according to claim 11, wherein sleep monitor:

- establishes a normative tidal volume and normative respiratory rate of the patient with the minute ventilation sensor sensed during the sleep state;
- periodically sensing the patient's tidal volume and respiratory rate with the minute ventilation sensor; and
- confirming that the patient is awakening from the sleep state when the patient's tidal volume and respiratory rate gradually rise and are sustained at elevated levels respectively above the normative tidal volume and the normative respiratory rate by a threshold amount.

13. The vagus nerve neurostimulator according to claim 1, wherein the pulsed electrical signal further comprises a signal ramp-up time and a ramp-down time.

14. The vagus nerve neurostimulator according to claim 13, wherein the output current, the signal frequency or the pulse width of the pulsed electrical signal is modified during the ramp-up time.

15. The vagus nerve neurostimulator according to claim 13, wherein the output current, the signal frequency or the pulse width of the pulsed electrical signal is modified during the ramp-down time.

16. The vagus nerve neurostimulator according to claim 1, wherein the duty cycle comprises a value in a range of 5% to 20%.

17. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor upon sensing the change in sleep state indicative of awakening causes the pulse generator to increase the intensity of the electrical signal by increasing a frequency of the electrical signal.

18. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor upon sensing the change in sleep state indicative of awakening causes the pulse generator to increase the intensity of the electrical signal by increasing an output current of the electrical signal.

19. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor upon sensing the change in sleep state indicative of awakening causes the pulse generator to increase the intensity of the electrical signal by increasing a duty cycle of the electrical signal.

20. The vagus nerve neurostimulator according to claim 1, wherein the sleep monitor upon sensing the change in sleep state indicative of awakening causes the pulse generator to increase the intensity of the electrical signal by increasing a pulse width of the electrical signal.

* * * * *

| | | | |
|---------------|---|---------|------------|
| 专利名称(译) | 植入式神经刺激器实施的方法，用于增强心力衰竭患者通过迷走神经刺激觉醒 | | |
| 公开(公告)号 | US9393419 | 公开(公告)日 | 2016-07-19 |
| 申请号 | US14/547342 | 申请日 | 2014-11-19 |
| 申请(专利权)人(译) | Cyberonics公司，INC. | | |
| 当前申请(专利权)人(译) | Cyberonics公司，INC. | | |
| [标]发明人 | LIBBUS IMAD AMURTHUR BADRI KENKNIGHT BRUCE H | | |
| 发明人 | LIBBUS, IMAD AMURTHUR, BADRI KENKNIGHT, BRUCE H. | | |
| IPC分类号 | A61N1/36 A61B5/00 A61B5/0205 A61B5/11 A61B5/0464 A61B5/08 A61N1/362 A61B5/0452 | | |
| CPC分类号 | A61N1/36139 A61B5/0205 A61B5/4836 A61B5/686 A61N1/36053 A61N1/36057 A61N1/36114 A61N1/36157 A61B5/0452 A61B5/0464 A61B5/08 A61B5/0816 A61B5/1118 A61B5/4809 A61N1/3621 A61B5/0245 A61B5/4812 A61N1/0551 A61N1/36171 A61N1/36175 | | |
| 代理机构(译) | FOLEY & Lardner的律师事务所 | | |
| 其他公开文献 | US20150073511A1 | | |
| 外部链接 | Espacenet USPTO | | |

摘要(译)

提供了一种植入式神经刺激器实施的方法，用于在患者通过迷走神经刺激从睡眠中苏醒时控制快速性心律失常。包括脉冲发生器的可植入神经刺激器被配置成以导致在包括患者的颈部迷走神经的神经元纤维内的动作电位的产生和传播（在传入和传出方向上）的方式递送电治疗刺激。存储脉冲发生器的操作模式。参数地定义和调整增强剂量的电治疗刺激，以防止患者从睡眠状态苏醒至电脉冲的连续循环，间歇和周期性开-关循环中的至少一个时引发或破坏快速性心律失常。定义了其他操作模式，包括维持剂量和恢复剂量。通过至少一个传感器监测患者的生理状态以检测患者的觉醒，其激活增强剂量的递送。

